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BASHAR WADIH BADRAN.  Transcutaneous Auricular Vagus Nerve Stimulation 
(taVNS): Development, Safety, Parametric Optimization, and Neurophysiological 
Effects. (Under the direction of Mark S. George) 
 
Cervically implanted vagus nerve stimulation (VNS) is a FDA-approved treatment for 
epilepsy and major depressive disorder (MDD). Additionally, VNS is a reemerging area 
of interest, showing promise in numerous animal studies with significant translatable 
applications. The cost, surgical risk, and human translation difficulty makes noninvasive 
VNS a highly-desired alternative.   
 
We have developed a transcutaneous auricular vagus nerve stimulation (taVNS) system 
that electrically stimulates the auricular branch of the vagus nerve (ABVN). We aimed to 
answer the following questions in this body of work: 1) whether taVNS is safe and 
feasible 2) if taVNS stimulates the vagus system similarly to implanted VNS 3) if the 
neurobiological effect of taVNS is similar to implanted VNS.  
 
We measured physiological recordings in healthy adults during taVNS to determine 
whether taVNS has vagus-mediated effects. In our first trial (n=15), we explored the 
physiological effects of 9 various stimulation parameter combinations (various pulse 
widths and frequencies) as a broad search of the physiological effect. A second, follow-
xiv 
up trial was conducted (n=20) to determine the best candidate parameter that optimally 
activates the parasympathetic nervous system. Lastly, we developed and conducted a 
novel concurrent taVNS/fMRI trial (n=17) to determine the neurobiological effect of 
taVNS and its afferent targets. All three trials consisted of 2 visits each, in a randomized, 
controlled, crossover design in which taVNS was delivered to either the left tragus 
(active) or earlobe (control).  
 
The first physiological trial revealed relevant, immediate heart rate decreases during 
taVNS followed by a sympathetic rebound upon termination of stimulation. Of the nine 
parameters tested, two had the largest effect on heart rate (500µs, 10Hz; 500µs, 25Hz). 
These two parameters were tested in the follow-up trial, which demonstrated that both 
parameters decrease heart rate, with 500µs 10Hz having the largest physiologic effect. 
Lastly, findings from the taVNS/fMRI trial demonstrate the neurobiological effect of 
taVNS mimics that of cervically implanted VNS and targets several cortical and 
subcortical vagus afferent pathway targets. 
 
taVNS in our paradigms was feasible, safe, and demonstrated neurobiological effects that 
are similar to implantable VNS. Future trials should conduct parametric optimization 
using the taVNS/fMRI protocol as it reliably targets vagus nerve afferents as well as 






OVERVIEW OF VAGUS NERVE STIMULATION (VNS) 
 
Human Anatomy of the Vagus Nerve 
Cranial Nerve X 
Cranial nerves (CN) serve as a pathway for which information is exchanged between the 
central nervous system (CNS) and the periphery. It would not be possible to integrate 
outside sensory information with the CNS without CNs. There are 12 cranial nerves (1), 
all of which play an important role in human sensation and perception. Important senses 
relied on daily, such as smell (CN I), vision (CN II), hearing (CN VIII), and taste (CN 
IX) are all relayed to the brain from the periphery via cranial nerves. 10 of the 12 CN’s 
first point of entry into the CNS is through the brainstem and have widespread afferent 
cortical and subcortical targets and effects. 
 
CN X, otherwise known as the vagus nerve, is a mixed sensory and motor nerve that 
originates from the medulla in a region known as the nucleus tractus solitarius (NTS). 
Latin for “wandering nerve,” the vagus nerve’s efferent projections travel throughout the 
thorax and abdomen, targeting nearly every major organ in the body. The vagus nerve’s 
primary role serves to monitor and regulate the organs depicted in figure 1-1a (2)  
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Figure 1-1 Schema of the Vagus Nerve. a) Visualization of the vagus nerve path 
through the human torso. The vagus nerve exits the brain and wanders vertically down 
through the entire human torso targeting nearly every major organ in the body. Listed are 
some of the major organs and their functions modulated by the vagus nerve.  b) A cross 
section of the vagus nerve. This cross-sectional diagram demonstrates how the vagus 
nerve is composed of multiple bundles of nerves. The vagus nerve houses over 100,000 
individual nerves, each compartmentalized into bundles and surrounded by gristle. These 
numerous bundles form one large nerve known as the vagus.   
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and convey information to the CNS (afferent projections) as well as from the CNS to the 
organs (efferent projections). It’s efferent effect is primarily parasympathetic (3), as the 
vagus releases acetylcholine (ACh) onto its targets, which binds to muscarinic Ach 
receptors inducing their behavioral effects. 
 
The vagus nerve is not one large nerve, but rather a large track of nerve bundles 
surrounded by gristle (Figure 1-1b) housing over 100,000 individual nerves. These 
nerves are about 80% afferent projecting nerves and 20% efferent nerves (4), although it 
is nearly impossible to determine exactly which nerves serve what purpose given its 
complexity. It is also extremely difficult to isolate behavioral or physiological effects 
from an individual nerve within the bundle, as intricate in-vivo microsurgery is required. 
 
Peripheral Targets 
Nearly every major organ in the human body has a connection to the vagus nerve, which 
enables bidirectional communication of information regarding relevant bodily functions 
performed by the organ. Summarized in (Figure 1-2) are functional domains that these 
target organs can be classified into: cardiovascular (heart), ingestion (esophagus, tongue), 
metabolism (stomach, intestine), inflammation (spleen), glucose regulation and toxin 
filtration (pancreas, liver, kidney).  These domains are integral to daily life activities and 





Figure 1-2 Behavioral domains that the vagus nerve regulates. The vagus nerve has 
bi-directional communication with the periphery. It receives input from these organs as 
well as sends centrally driven information to them to regulate their action. This vast two-
way communication tract can be utilized to treat peripheral diseases of target organs and 
central neuropsychiatric diseases. 
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Afferent (periphery to central) vagal communication can be easily exemplified by the 
feeding satiety signal. Cholecystokinin (CKK) and leptin are produced in the gut when an 
individual eats and stomach fills with food. CCK and leptin generate a satiety “signal” 
transmitted from the stomach to the CNS via the vagus nerve. This signal alerts the brain 
and elicits a termination of feeding behavior (5, 6).  
 
An example of efferent vagal communication is best demonstrated by the 
parasympathetic relaxation of heart rate (7, 8). This parasympathetic response is initiated 
in the periventricular nucleus (PVN) of the hypothalamus, sending efferent projections 
down through the NTS and to the heart and lungs, releasing ACh and slowing heart rate 
(9). This bidirectional communication and direct regulation of function of vital bodily 
organs makes for an extremely large and intricate nerve system. 
 
Afferent Brain Targets 
The first entry point of the vagus nerve into the CNS (Figure 1-3) is the NTS (10, 11). 
From the NTS there are direct projections to the locus coeruleus (LC) and parabrachial 
nucleus (PB) (12). These two brain regions are responsible for many of the behavioral 
effects of vagus nerve stimulation (VNS), which will be discussed in the later part of this 
chapter. Krahl et al demonstrated lesions of the LC cause the anti-epileptic effect of VNS 




Figure 1-3 Afferent pathway of the vagus nerve. The first point of entry of the vagus 
nerve is in the nucleus tractus solitarius (NTS). From there the signal is immediately 
projected up to the locus coeruleus (LC), the primary producer of norepinephrine for the 
brain. From there the signal propagates in three directions 1) directly to the cerebellum 
(CB) 2) up to the thalamus (THAL), and 3) frontally to the hypothalamus (Hyp), 
amygdala (Amg), and nucleus basalis (NBM). Passing these deeper brain structures, the 
afferent path leads to important mood and cognitive processing networks like the orbital 
frontal cortex (OFC), cingulate cortex (Cing), and prefrontal cortex (PFC). Effects are not 
limited to the named structures, as there are unlisted widespread, diffuse cortical effects.  
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The LC is the primary producer of norepinephrine (NE) in the CNS, a key 
neurotransmitter and alert signal of the brain. From the LC there are ascending 
projections branching directly to the thalamus (Thal), hypothalamus (Hyp), cerebellum 
(CB), orbitofrontal cortex (OFC), prefrontal cortex (PFC), cingulate gyrus (Cing), 
amygdala (Amg) nucleus basalis of meynert (NBM) and the rest of the cerebrum (14).  
 
Although NE is the primary afferent neurotransmitter involved in the afferent vagal 
pathway, the LC also influences serotonin release through direct projections to the dorsal 
raphe nucleus (DRN) (15) which is the brain’s primary producer of serotonin and 
independently has a wide range of ascending brain targets, many of which overlap the 
ascending LC pathway. 
 
Early Vagus Nerve Stimulation 
Initial Animal Trials Exploring VNS 
In the early 20th century, Otto Loewi conducted a famous experiment (16) that is credited 
with discovering neurotransmitter communication in nerves. Loewi stimulated the intact 
nerve of a frog heart maintained in a solitary perfusion chamber. He observed the slowing 
of heart rate and collected the chamber fluid, transferring the fluid to a second chamber, 
which contained a denervated frog heart. When the second, untethered heart was bathed 
in the new fluid, it beat rate also slowed. This study concluded that the fluid must contain 
a chemical released upon electrical stimulation of the nerve which Loewi called 
“vagusstoff.” Eventually, this chemical was validated and now known as acetylcholine 
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(ACh). This discovery earned Loewi the Nobel Prize in Physiology or Medicine in 1936, 
shared with Sir Henry Hallett Dale for “their discoveries relating to chemical 
transmission of nerve impulses.”  
 
Following Loewi’s experiment which demonstrated th peripheral effects of direct 
electrical VNS, there were several important animal studies (Table 1-1) exploring the 
central effects of VNS leading up to the inception of VNS as a human therapeutic tool to 
eventually be used for intractable epilepsy and major depressive disorder (MDD). These 
trials span a series of half a decade and are not assumed to be the only VNS trials 
conducted during this time, but rather pivotal positive trials that served as integral 
findings in the development of VNS as a modality. They all involve direct, in-vivo 
electrical stimulation of the vagus nerve, as Loewi did to demonstrate neuronal and 
behavioral changes.  
 
Bailey and Bremer conducted the first of these studies in 1938 (17). This study 
demonstrated that VNS in cats increased synchronized electrical potentials of the orbital 
frontal cortex as measured by electrogram. VNS was then conducted in monkeys under 
anesthesia by MacLean and Pribram in 1949 and reported in MacLean’s book in 1990 
(18). Their study suggested changes in the lateral frontal cortex associated with 
stimulation. Dell and Olson conducted their own VNS study in awake cats in 1951 (19) 
which demonstrated relevant slow-wave changes in the amygdala and thalamus. Radna 
and MacLean followed up with a second VNS trial with monkeys in which they   
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Table 1-1. Early VNS studies leading to human trials 
Year Author Model Brain region Findings 
1938 Bailey & Bremer Cats OFC 
↑ synchronized electrical 
signals on EEG 
1949 
MacLean & 
Pribram Monkeys LFC 
Inconsistent, slow waves 
on EEG 





Slow wave response on 
EEG 
1981 Radna & MacLean Monkeys Limbic ↑ single unit activity 
1981 Radna & MacLean Monkeys Striopallidum ↑ single unit activity 
1987 Zabara et al.  Dogs Cortical 
Medication-induced 
seizure termination. 
Protection 4x stimulation 
period. Parameters 
established. 1992 Zabara et al.  Dogs Cortical 
OFC-Orbital Frontal Cortex; LFC-Lateral Frontal Cortex; Amg-Amygdala, Thal-
Thalamus, ARS-Anterior Rhinal Sulcus 
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demonstrated single unit activity effects as a result of stimulation in the thalamus, 
cingulate, and limbic structures (20, 21). 
  
The invention of therapeutic VNS is credited to Dr. Jacob Zabara, who was the first 
individual to consider VNS as a treatment for neurological disorder. In the late 1980’s, 
Zabara conducted a VNS trial in dogs that had pharmacologically induced seizure 
disorder (strychnine) (22, 23). VNS in these dogs elicited cortical changes as measured 
by EEG and halted motor seizures and tremors. He then conducted a follow-up trial, 
again in canines, optimizing VNS as a seizure suppressor and also demonstrated that 
VNS had a behaviorally positive long-term effect that persisted beyond the stimulation 
period (24). These studies are cited as the pivotal animal trials that justified VNS as an 
implantable therapeutic device for humans. 
 
VNS for Epilepsy in Humans 
Although Zabara is credited with the innovated application of therapeutic VNS in 1985, it 
is forgotten that a century prior, an American neurologist by the name of James Leonard 
Corning suggested that seizures could be attenuated using transcutaneous vagal nerve 
stimulation through the neck. In 1883 (25, 26) Corning built a device (Figure 1-4, US 
National Library of Medicine Public Domain) which he hypothesized would stimulate 
the vagus nerve, decrease cerebral blood flow, and reduce epileptic seizure frequency and 














Figure 1-4. The Corning fork. Developed in 1883 by James L. Corning, this device 
served two purposes 1) bilateral carotid compression, which was believed to treat 
epilepsy, and 2) direct electrical stimulation to the carotid sheath, stimulating the bilateral 
pneumogastric nerves as a prophylactic epilepsy therapy. This figure is from the US 
National Library of Medicine where the original manuscript may be found and falls under 
public domain use (26).  
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Corning, his colleagues did not adopt his technology and it disappeared by the early 
1900’s.  
  
In 1987, Zabara co-founded Cyberonics, Inc. (now LivaNova), along with Reese Terry, 
and began developing a human VNS device based on his promising animal trials. The 
first human implanted with a VNS device was in 1988 at Wake Forest Gray Medical 
School in North Carolina by Dr. J. Kiffen Penry and neurosurgeon William Bell  (27). 
Eventually, four patients were implanted in this inconclusive safety and feasibility trial. 
Side effects were described (hoarseness, stimulation sensation, hiccups). Several more 
clinical trials (28, 29) were conducted in the early 1990’s leading up to European 
approval of the Cyberonics VNS device to treat epilepsy in 1994 (30, 31), and subsequent 
United States FDA approval in 1997. Degorgio et al (32) demonstrated nearly 20% of 
individuals had a >75% reduction in seizure frequency at 12-months post implantation, 
and a median reduction on seizure frequency of nearly 50%. Sackeim et al (33) 
demonstrated the acute response rate in refractory epilepsy as being approximately 30%.  
As of 2017, according to Cyberonics, over 100,000 patients worldwide have been 
implanted with a VNS device as a treatment for intractable epilepsy.  
 
Modern Vagus Nerve Stimulation  
Implantation and Programming 
A VNS system can be implanted by any surgeon trained in the head and neck. It is an 
outpatient surgical procedure with few serious complications (32, 33). The implantation 
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site is the left branch of the mid-cervical vagus nerve, which is accessed through the 
neck. A helical bipolar electrode (three-helix cuff) is wrapped around the nerve (Figure 
1-5). Wires are run from the electrode cuff to a subcutaneously implanted pulse generator 
in the left chest. This pulse generator, or “can” contains a lithium battery and constant 
current pulse generator with a lifespan of approximately 5 years although second 
generation devices are being developed to have lifespans of over 10 years.  
 
Following implantation, there is a two-week period in which the patient can recover from 
the minor procedure. The patient then returns after this two-week period to have their 
pulse generator programmed by their providing physician in an outpatient setting. 
Programming of the device is completely wireless, using a proprietary wand that 
connects to the device using radio frequency (RF). Through a portable computer, the 
wand can program specific parameters (current (mA), duty cycle (on/off time) and 
frequency (Hz)).  The pulse generator also contains a reed switch, which enables the 
patient to turn off the device by swiping a strong static magnet over it. This enables the 
patient to test if the device is still functioning, but more importantly allows for user 






Figure 1-5. Modern cervically implanted VNS. a) VNS systems have two key 
components 1) an implantable pulse generator (IPG) which contains a battery and 
microcontroller delivering current, and 2) bipolar helical electrodes that wrap around the 
left cervical vagus nerve. b) This zoom view of the vagus nerve demonstrates how the 




The question of optimal parameters arises with every form of neuromodulatory 
techniques such as transcranial magnetic stimulation (TMS), electroconvulsive therapy 
(ECT) and deep brain stimulation (DBS). The parameter space for these modalities is 
extremely vast. As presented in Figure 1-6, pulse width (µs), current (mA), frequency 
(Hz), duty cycle (on/off time), and dose titration (% threshold) are all parameters that can 
be manipulated to optimize desired behavioral response. Although the parameter space is 
large, many of our current therapies are based on the effects seen in preclinical animal 
studies, which are then translated to human studies. 
 
Initial trials of the anti-seizure effect in a canine model demonstrated in Zabara’s trials 
determined an optimal stimulation frequency of 20-30Hz, at a constant 20V with a pulse 
width of 200µs (24). Those findings guided initial multi-site clinical trials that eventually 
could determine optimal stimulation parameters to reduce seizure frequency in epilepsy 
patients.  
 
One notable difference is the pulse width increased by a magnitude of more than 2 (from 
200µs to 500µs) from animal trials to human trials. This is a result of neuronal chronaxie, 
which is the minimum pulse width size required to fire a nerve fiber using an electric 
current. Imach and Ranck discuss that a pulse width of 200-700µs is the optimal pulse 
width to fire nerve fibers as it maximizes the peak firing percentage rate while 




Figure 1-6 Direct electrical current waveform. Direct square wave electrical current 
can be delivered at various parameters. This figure demonstrates key properties of the 





require significantly higher voltages to consistently and reliably depolarize nerves, 
whereas larger pulse widths, although they maximally depolarize nerves, demonstrate 
higher side effects and are using electrical energy from the device inefficiently.  
 
Agnew and McCreery explored the question of optimal stimulation frequency the initial 
1987 anti-epileptic findings by (36, 37). They demonstrated that higher frequency ranges 
(>50Hz) in fact cause damage to the vagus nerve. This damage is not seen in lower 
operating frequencies. Low frequencies (1Hz) were explored in human clinical trials as a 
control (32) (38)and showed minimal behavioral effects, effectively constraining the 
frequency space in humans to between 1Hz and 50Hz. 
 
The current accepted parameters for VNS are as follows: current– 0.25-0.75mA; pulse 
width– 250-500µs; frequency– 20-30Hz; duty cycle – On 30s, Off 5min. These 
parameters are set as ranges and increased to a maximally tolerable level dependent on 
immediate side effects listed as hoarseness of voice, throat pain, coughing and headache 
(32, 33).  
 
VNS for Resistant Depression 
During the late 1990’s, as the VNS for epilepsy pivotal FDA-trials were coming to an 
end, a clerk at the Florida hotel all follow-up patients stayed at noticed their moods were 
improving. Anecdotally, and lacking objective depression measures, this was relayed to 
the study team and followed-up by a prospective study in 14 individual (39) showing a 
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trend of mood-enhancing effects of VNS. In retrospect, given the wreath of depression 
neuroimaging research accessible today, VNS for depression is accepted to potentially 
have an anti-depressant effect with its afferent brain targets.   
 
Several multi-site trials were conducted in the early 2000’s to determine whether VNS 
was an effective antidepressant in patients with extremely resistant major depressive 
disorder (MDD). The first trial (33, 40, 41) was a four-site, open-label trial in 59 patients. 
Acutely, 8 weeks of VNS produced a 31% response rate in these patients with a 15% 
remission rate. Over time, these individuals improved, with the two-year response and 
remission rates increasing to 44% and 22% respectively. European open-label trial 
findings were similar to their US counterparts (42). These findings posed Cyberonics to 
conduct a pivotal FDA-approval seeking randomized control trial in 222 extremely 
resistant MDD patient. The findings of this pivotal trial were disappointing, with a large 
sham response rate (10%) and reduced overall effect by condition, demonstrating non-
significant acute benefits compared to sham (43). These patients were followed for two 
years after implantation and the response rate more than doubled at two year follow up 
compared to the acute treatment phase. There seems to be a cumulative, long-lasting 
effect of VNS that is not being accounted for and is still unknown mechanistically.  
 
VNS was FDA approved for chronic or recurrent depression in 2005 based on the 
findings by George et al. (44). This study demonstrated that when VNS therapy was 
compared against treatment as usual in a multi-site comparison trial with a followed, non-
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implanted matched cohort receiving treatment as usual (TAU), VNS produced 
significant, long-term, durable benefits. It still lacks class 1 evidence as a treatment for 
depression and as of 2017 plans are being developed by LivaNova (acquired Cyberonics 
in 2016) to conduct a pivotal, randomized controlled FDA trial for class 1 evidence of 
VNS as a therapy for chronic recurrent depression.  
 
Key VNS Functional Neuroimaging Trials 
Several neuroimaging trials have been conducted using positron emission tomography 
(PET) and functional magnetic resonance imaging (fMRI). Initial VNS imaging trials 
were conducted in 1992 by Garnett et al using positron emission tomography (PET) 
scanning (45). PET detects pairs of gamma rays, which are emitted by a radiotracer that 
is injected into the patient and used as a measure of metabolism. Oxygen 15 (H215O PET) 
is an excellent tracer for neuronal activity, as the cells require oxygen for metabolism and 
neuronal firing. In this early trial in patients implanted with a stimulator for epilepsy, 
VNS-increased blood flow was discovered in the thalamus and cingulate. This study was 
followed-up by Henry and colleagues (46) who demonstrated areas of increased blood 
flow in the brainstem, thalamus, and hypothalamus and decreased blood flow in the 
medial temporal cortex and hippocampus. These two studies, although not inclusive of all 




fMRI uses strong magnetic fields (>1.5T) to measure blood oxygen level dependent 
(BOLD) signals in the brain (47) that serve as a surrogate marker of neuronal activity. 
Oxygen binds to hemoglobin and is carried to neurons in the brain for metabolism. The 
differences in magnetic properties of oxygenated vs. deoxygenated hemoglobin make this 
imaging modality possible.  
 
Faraday’s law of induction dictates that electricity is induced when there is a changing 
magnetic field around a coil of wire which poses concern for conducting fMRI combined 
with VNS as the electrodes may heat up causing harm to the patient and the pulse 
generator may function improperly due to the magnetic field of the scanner. Using a 
specific orientation of implantation for the pulse generator as well as a specific head coil 
to decrease the magnetic field delivered to the VNS system, Bohning et al (48) developed 
the first VNS/fMRI method at the Medical University of South Carolina (MUSC). This 
landmark study was followed by an important VNS/fMRI study in depressed adults 
showing the frequency and dose effects of VNS in a pathologic group (49) and 
subsequently by Mu et al (50).  
 
Nahas et al (51) followed by conducting several longitudinal VNS/fMRI scans on 
patients to explore the brain effects of VNS as a function of time. His findings reveal that 
BOLD signals increased as a function of how depressed the patient was and how strong 
the stimulation parameters were. Serially over time, these overall BOLD activations 
decreased. Since then, there have been several VNS/fMRI studies from groups all over 
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the world (48-54) demonstrating relevant BOLD signal intensity increases in vagal 
afferent brain regions which are summarized in Table 1-2. 
 
Recent Strides in VNS 
Promising Animal Trials 
VNS is seeing a resurgence in the scientific community over the past 15 years. In the late 
1980’s and early 1990’s, much of the literature was attempting to determine the basic 
feasibility and method of VNS. After that was established, the mid-1990’s to early 2000s 
were dominated primarily by human clinical trials, translating the early animal studies 
into two FDA-approved treatments for intractable epilepsy and chronic resistant 
depression.  Since the mid-2000’s to today, the field of basic VNS research has boomed, 
with hundreds of papers being published a year on this interesting form of 
neuromodulation. VNS has been explored in dozens of different disease animal models, 
but the most promising are in the following central and peripheral disorders: obesity, 
inflammation/sepsis, tinnitus and stroke. This section will highlight some of the hallmark 
studies that are of high impact in the field and will most likely (if not already) be 
translated into human studies.  
 
The first promising animal trial exploring the effects of VNS (implanted in the thorax 
near the stomach rather than cervical for epilepsy and depression) dates to 2001 in which 




Table 1-2. VNS/fMRI studies 
Year  Author n Subjects Parameters Control Findings 
2001 
Bohning et 
al.  9 TRD 
20 Hz; 500 µs; 0.5-
1.25 mA; 13 sec on, 
103 sec off n/a 
Feasibility of fMRI to measure 
VNS effects on TRD patients 
2002 
Lomarev et 
al. 6 TRD 
5 Hz or 20 Hz; 500 
µs; 0.25-1.25 mA; 13 
sec on, 103 sec off 
Yes, 
5 Hz      
Tone  
20 Hz > 5 Hz BOLD response.                               
20 Hz > 5 Hz to tone (arbitrary 
stimulus)  
2004 Mu et al.  12 TRD 
20 Hz; 0.25-1.25 mA 
(max tolerated at 500 
µs); 13.6 sec on, 41 
sec off  n/a 
130 µs - insufficient global 
activation                                             
250 µs - sufficient activation & 
deactivation                                                           
500 µs -  insufficient global 
deactivation     
2007 Nahas et al.  9 TRMD 
20 Hz; 500 µs; 
variable mA; 13.6 sec 
on, 41 sec off  
Yes, 
0 mA 
VNS acutely activates R insula, 
deactivates vmPFC.  
2002 
Sucholeiki 
et al.  4 Epilepsy varied n/a 
Feasibility of fMRI to measure 
VNS effects on epilepsy patients 
2002 
Narayanan 
et al.  5 Epilepsy 
30 Hz; 250 µs; 0.5-
2.0 mA; 30 sec on, 30 
sec off (48 x1) none 
VNS induced ↑ activity in: b/l 
thalami, b/l insula >> L BG, L 
Postcentral g, R post. STG, L>R 
imOcc g. 
2003 Liu et al.  5 Epilepsy 
30 Hz; 250 µs; 1.25-
1.75 mA; 30 sec on, 
66 sec off  
 
2 patients with thalamic 
activation has greatest seizure 
response. All patients had frontal 
and occipital activation. 
TRD-Treatment resistant depression; TRMD-Treatment resistant mood disorders; vmPFC- ventromedial 
Prefrontal Cortex; b/l- bilateral, R-right, L-left; BG-basal ganglia; STG- superior temporal gyrus; imOcc- 
inferomedial occipital gyrus 




(55). There have been several follow-up trials since, demonstrating VNS decreases food 
intake and weight gain (56-58). The most notable of these trials was the 2010 trial in 
which obese Gottingen minipigs  (58) were implanted with VNS devices and not only 
lost weight but opted for a healthier diet. These findings translated to human clinical 
trials in the 2012 EMPOWER randomized control trial (59) testing blockade of the vagus 
nerve for weight loss. Unfortunately, the EMPOWER trial did not find significant 
behavioral effects compared to sham. This trial was followed by a 2014 large scale, 
multi-site RCT called ReCharge (60) which addressed limitations from the EMPOWER 
trial and demonstrated significant, long-term weight loss benefits that eventually became 
FDA-approved in 2015. 
 
The human inflammatory system is a body’s natural response to pathogens and trauma. 
These responses can be triggered by infectious and non-infections conditions (61) and 
when left unchecked, the inflammatory cascade becomes a systemic response that can 
become deadly. In 2000 a study published in Nature (62) described a landmark study in 
which rats were given a lethal endotoxic event that was intended to develop into septic 
shock. After administration of the endotoxin, electrical stimulation of the vagus nerve 
decreased the release of pro-inflammatory cytokines (tumor necrosis factor (TNF), 
interleukins 1B, 6, and 18). Ultimately this suppression of inflammatory cytokines 
prevented the rats from entering septic shock from the endotoxin. Since then there have 
been dozens of trials exploring the anti-inflammatory effect of VNS, most notably 
attenuating heart failure progression in canines (63). 
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Tinnitus is an auditory phantom perceptual disorder in which individuals hear a sound in 
the absence of an external stimulus. The leading cause of tinnitus is acoustic trauma (64) 
in which hair cells are damaged and no longer provide cochlear input of specific 
environmental auditory frequencies, causing a spontaneous overexpression of that 
frequency in the auditory cortex that presents as internally generated sound. To date there 
are no effective treatments for tinnitus; often patients are sent home with this debilitating 
condition and told to manage it on their own.  
 
Michael Kilgard’s group at the University of Texas, Dallas have demonstrated that 
pairing cervically implanted VNS in a tinnitus rat model paired with auditory stimulus is 
able to reorganize the auditory cortex and reverse the pathological changes that induce 
tinnitus(65-68). When VNS was delivered to the rats in a tinnitus model, there was no 
decrease in tinnitus symptoms, neither were any symptom reductions seen with the tone 
therapy alone. This suggests there is a synergistic effect of VNS combine with a paired 
stimulus that is directing plastic changes to occur in the cortex. Kilgard calls this concept 
“targeted plasticity”(66) in which various cortical targets can be selectively changed 
dependent on the paired stimulus. This group is exploring VNS induced targeted 
plasticity as a treatment for other neurological disorders in animal models involving 
cortical reorganization, including stroke (69, 70) and have successfully moved into 
human clinical trials for both these promising treatments (71-73). 
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Lastly, VNS has been shown to rescue the brain if stimulation begins immediately after 
trauma. In 2009 a study by Ay et al (74) demonstrated a rescuing effect of VNS in a rat 
model of ischemic stroke. Rats that received vagal stimulation immediately after the focal 
cerebral ischemia had not only significantly better neurological scores compared to the 
control (non-VNS rats), but these rats also had infarcts that were nearly 50% smaller in 
area than the control rats. This was replicated in 2011 by the same group (75) and is very 
promising as a future potential immediate therapy for ischemic stroke. VNS seems to be 
neuroprotective and keeps ischemia from spreading. 
 
Noninvasive Vagus Nerve Stimulation (nVNS) 
Although cervical VNS is relatively safe and effective in seizure prevention (30, 76), the 
risks involved in surgical implantation as well as its high procedural cost (about $30-
50,000) makes it less appealing and accessible as a treatment modality. Additionally, 
only about 30% of implanted patients have a clinical response, despite undergoing 
surgery and spending large amounts of money. Having a non-invasive method as an 
alternative or to determine ultimate responders would greatly improve VNS acceptance 
as a treatment modality.  
 
Noninvasive VNS (nVNS) can potentially be administered at two locations. The first and 
most obvious method is via transcutaneous electrical stimulation of the cervical vagus 
accessed through neck near the carotid artery (carotid sheath). This method, known as 
transcutaneous cervical VNS (tcVNS) was first described 125 years ago by Corning (26). 
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It can be delivered experimentally in a research setting by attaching transcutaneous 
electrical nerve stimulation (TENS) electrodes to the neck and stimulating the underlying 
tissue and nerve with either alternating or direct current high-frequency electrical 
stimulation. A commercially available device, marketed as gammaCore, safely delivers 
tcVNS (25Hz, constant current <60mA) to the cervical vagus nerve. This device has been 
explored to treat various neurological disorders, including headache, migraine (77-80). 
The optimal parameters and duty cycle is still unknown and needs to be developed 
further, although as of early 2017 the gammaCore device gained US FDA-approval. 
 
nVNS may also be administered through the auricular branch of the vagus nerve (ABVN) 
that innervates the ear, more specifically the conchae and the external auditory canal (81). 
This noninvasive method is called transcutaneous auricular vagus nerve stimulation 
(taVNS) was first developed in 2000 (82). Since then, there have been several groups that 
have conducted studies on this novel form of neuromodulation (83-88) which uses low 
electrical current stimulation (<10mA) to stimulate the auricular vagus nerve. Many 
laboratories conduct this novel method experimentally by building their own, miniature 
electrodes that target this nerve and there is also a commercially available device 
(European only, not for purchase in the US) called Nemos® claiming to treat epilepsy 
using their proprietary device.  
 
Whether nVNS enters the brain via the brainstem and targets vagal afferent brain regions 
has been explored in a handful of studies combining nVNS with fMRI. There have only 
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been five taVNS/fMRI trials in which stimulation was conducted concurrently with 
imaging (89-93) and one tcVNS/fMRI trial (94). These studies are summarized in detail 
in Chapter 4 of this dissertation. In general, these studies demonstrate similar findings to 
the cervically implanted VNS/fMRI, with relevant BOLD signal activations and 
deactivation in the afferent vagal brain regions (brainstem, thalamus, insula, amygdala). 
Brainstem activation is inconsistently viewed in these functional imaging trials, as the 
sample sizes are often small and breathing artifact often washes out this small region of 
interest.  
 
There are two major problems with nVNS: 1) the parameter space is unknown, and 2) 
surrogate markers of vagal activation are difficult to determine. With cervically 
implanted VNS, the vagus nerve is directly stimulated, whereas nVNS jumps through 
several hoops to get to this point. Firstly, the electricity is delivered through the skin 
targeting underlying nerves that are not visible. This requires more electricity to be 
delivered in the case of tcVNS, potentially recruiting surrounding nerves 
(glossopharyngeal nerve, laryngeal nerve) in the area and losing its focal effect, or in the 
case of taVNS, recruitment of off target nerves in the area (auriculotemporal nerve, lesser 
occipital nerve). taVNS still does not have a consensus target location to stimulate and 
there is a debate that has arisen as to whether one targets the tragus or the conchae of the 
ear. Aside from off-target questions, current stimulation parameters arise. Stimulation 
current intensity (mA), frequency (Hz), and pulse width (µs) all vary throughout the 
various early nVNS trials in the literature.  
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Before the field begins large-scale use of nVNS, optimal stimulation targets and 
parameters must be determined. It is common to rush to clinical trials with novel 
methodology, but often these trials risk failure due to the lack of pre-clinical 
optimization. This lack of optimization is the impetus for this dissertation body of work 
which is consists of the systematic, parametric testing and optimization of taVNS which 
is integral to guiding future trials. This dissertation describes three sequential studies 
conducted at the Medical University of South Carolina. The first two experiments 
determined feasibility, safety, and optimal taVNS parameters that modulate the 
parasympathetic nervous system in healthy adults. We suspected that heart rate can be 
used as a surrogate marker of vagal activation. The third experiment is a neuroimaging 
trial which taVNS was administered in the fMRI scanner to explore the direct brain 
effects. The combination of these three trials were planned to give this new field a 



















STUDY 1: A CONTROLLED TRIAL EXPLORING THE SAFETY, 
FEASIBILITY and HEART RATE EFFECTS of taVNS 
 
Study Summary  
Background: Transcutaneous auricular vagus nerve stimulation (taVNS) is hypothesized 
to stimulate the vagal system via the auricular branch of the vagus nerve (ABVN). The 
optimal parameters of stimulation are still unknown and given the parasympathetic role 
of the vagus nerve, it is important to establish a safety profile of this novel form of 
stimulation, as well as the effect of various parameters on heart rate (HR). 
 
Objective: The objective of this study is to investigate the safety profile and HR effects 
of 1-minute sessions of nine various taVNS parameters (pulse width: 100µs, 200µs, 
500µs; frequency: 1Hz, 10Hz, 25Hz).  
 
Methods: We enrolled 15 healthy individuals in this 2-visit, controlled, crossover trial. 
Each experiential visit was identical, in which participants received either active (tragus) 
or control (earlobe) stimulation. 9 stimulation parameters were administered, each for 1 
minute flanked by a baseline and recovery period. Participants were monitored for 
adverse events while their HR was recorded the entirety of their visit. Statistical analysis 
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was conducted on overall effect of condition (all 9 parameters combined; active vs 
control) for the entire time course (120s) as well as a focused analysis on the independent 
stimulation period (60s) and recovery period (60s). Multivariate analysis exploring the 
individual parameter effects (active vs control) was also conducted.   
 
Results: An overall effect of condition was revealed comparing active taVNS to control 
for all parameters. No overall effect of condition was found on HR during the stimulation 
period although active taVNS was found to significantly suppress the sympathetic HR 
rebound in the post-stimulation period (p<0.001) compared to control. Upon multivariate 
analysis, several parameters of higher pulse width and frequency (500µs 10Hz and 500µs 
25Hz) significantly induced bradycardia during stimulation and attenuated the 
sympathetic recovery spike (100µs, 10Hz and 500µs 10Hz).  
 
Conclusion: taVNS is feasible and safe for 1-minute stimulation periods in healthy adults 
with no adverse events observed. Two specific parameters (500µs 10Hz and 500µs 25Hz) 
are revealed to be further studied as likely optimal parameters at modulating 
parasympathetic response via vagal activation.  
 
Introduction 
Autonomic nervous system 
The vagus nerve, as described in Chapter 1, is a large bundle of nerves that spans the 
entire length of the body and targets every major bodily organ. The autonomic effect it 
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has on these organs is primarily parasympathetic, with acetylcholine (ACh) being the key 
neurotransmitter released on these organs and responsible for this effect (16).  
 
The autonomic nervous system regulates vital organ behavior and is unconsciously 
activated in response to certain sensory triggers, most notably affecting heart rate (HR), 
respiration, and vasoconstriction/dilation (10). There are two independent and opposite 
autonomic systems (95). The first, known as the sympathetic nervous system (SNS), is 
generally accepted to be excitatory and accelerates HR, respiration, and vasoconstriction 
of vessels. This is known as the “fight or flight” response which allows for heightened 
arousal. The splanchnic nerve carries these excitatory signals to the viscera and release 
norepinephrine onto its target organs.  The second, independent system is the 
parasympathetic nervous system (PNS), which slows HR and respiration. In general, it 
elicits a slowing and relaxation of organs that are targeted. All parasympathetic nervous 
system signals are sent via the vagus nerve, which releases Ach onto the organs to induce 
the inhibitory effect. Both the SNS and PNS are tonically and reciprocally active to 
maintain body homeostasis. Both the SNS and PNS activity arise from signals sent from 
the hypothalamus, known as the central hub of the autonomic nervous system. 
 
The Effect of Cervically Implanted VNS on HR 
Otto Loewi demonstrated the slowing effects of the heart via the release of a ACh onto 
the heart in the late 1900’s(16).  Since then, as the autonomic nervous system was 
studied, hundreds of studies have demonstrated the slowing of HR as a major response of 
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activating the parasympathetic nervous system. This is easily demonstrated by the carotid 
massage (96, 97), a procedure in which gently rubbing on the vagus nerve via the carotid 
sinus stimulates the vagus and induces a parasympathetic slowing of the heart. 
 
A major concern during the inception and development of vagus nerve stimulation (VNS) 
is that direct electrical stimulation of the vagus nerve will elicit a powerful 
parasympathetic response. During clinical trials, this was heavily monitored for and 
tracked throughout implantation and treatment course (30). Anecdotally, there are 
theories suggesting implanting a VNS electrode on the right cervical vagus could induce 
more cardiac side effects than the left, although this was investigated in a VNS trial 
exploring both left and right VNS for chronic heart failure which demonstrated equal 
safety profiles (98).  
 
There also have been several trials suggesting VNS has no effect on HR. Early VNS trials 
by Holder (99) and Uthman (28) determined no change in HR in VNS implanted humans. 
Ramsay (100) retrospectively determined there was no HR effect in acute monitoring of 
epilepsy patients implanted with VNS. Setty A.B. and colleagues conducted a prospective 
trial explored the effect of VNS on ten individuals implanted with VNS for epilepsy and 
showed no change in cardiac rhythm during the 30s stimulation period (101). Contrary to 
these three early studies, a recent study in 2001 by Frei and Osorio showed a decrease in 
HR (bradycardia) immediately upon starting stimulation, followed by increased HR 
(tachycardia)(102). Although this was the first description of immediate HR effects of 
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VNS, their findings were highly variable between patients (no one consistent 
physiological signature), although a consistent pattern within patients.  
 
Rationale Behind Study 1 
Stimulating the vagus nerve in humans elicits a decrease in HR. Since the therapeutic 
VNS duty cycle is 30s and intensity relatively low, it is supposed that may explain the 
lack of major HR adverse effects.  To date, there have been no prospective studies 
conducted directly exploring the effects electrical stimulation of the ABVN via taVNS 
delivered to the ear on HR. 
 
If stimulating the ABVN enters the vagus pathway, safety should be highly considered as 
the parasympathetic effects of the vagus nerve may cause inadvertent adverse events. To 
demonstrate the feasibility and safety profile of this novel form of stimulation that is 
suspected to stimulate the vagus system, it is important to conduct a systematic, 
parametric study exploring the HR effects of various taVNS parameters. Additionally, 
given the large parameter space of taVNS, this trial was conducted to determine whether 
some parameters modulate the vagal system and HR more effectively than others, using 
HR modulation as a potential surrogate measure of optimal parameters. This is not 
intended to be an exhaustive exploration of parameters but rather a reasonable 
combination of high and low settings loosely based on prior cervically implanted trials 
(24, 27). We hypothesize parameters of higher energy density (larger pulse width, faster 
frequency) would be more effective at modulating HR in a similar manner as prior 
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We conducted a 2-visit, controlled, crossover trial in healthy individuals exploring the 
HR effects of taVNS. Individuals came to the Medical University of South Carolina 
(MUSC) brain stimulation laboratory for two separate 1-hour experimental visits 
(active/control visits, counterbalanced design). Each visit was identical except for 
stimulation condition (Figure 2-1a).  The trial was approved by MUSC Institutional 
Review Board (IRB) and is registered on ClinicalTrials.org (NCT02835885). 
 
Participants and Inclusion Criteria 
15 healthy adults (7 female) were enrolled after meeting the following inclusion criteria: 
Age 18-45, no personal or family history of seizure, mood, or cardiovascular disorders, 
no facial or ear pain, no recent ear trauma, no metal implants including pacemakers, not 
pregnant, no dependence on alcohol or recent illicit drug use, not on any pharmacological 
agents known to increase seizure risk (Bupropion, neuroleptics, albuterol, theophylline, 
antidepressants, thyroid medications, or stimulants).  
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taVNS Stimulation System and Parameters 
A custom developed stimulation system was developed at the MUSC Brain Stimulation 
Laboratory and used in this trial. It consists of a commercially available, FDA-cleared 
Digitimer DS7A constant current stimulator (Digitimer Ltd., USA) used with custom-
built electrodes (built by BWB and AWB) (Figure 2-2a).  Electrodes had a stimulation 
surface diameter of 1cm and Ten20 conductive paste (Weaver and Company, USA) was 
used to deliver stimulation to ear targets. Participants lay supine with their neck and head 
propped up in a comfortable position with a pillow. They were instructed to stay awake 
and maintain a still, comfortable position. Stimulation targets were prepped with alcohol 
swabs (70% isopropyl alcohol) to clean surface oils and decrease skin resistance. 
 
Stimulation parameters varied by pulse width (100µs, 200µs, 500µs) and frequency (1Hz, 
10Hz, 25Hz) creating 9 different combinations of stimulation parameters. These 
parameters were chosen to cover a wide range (low to high) of pulse width and 
frequencies. The current (mA) of electrical stimulation was delivered at 200% of each 
participant’s individual perceptual threshold (PT). A PT was conducted for each of the 
three pulse widths investigated in this trial (100µs, 200µs, 500µs) in which the lowest 
electrical current perceived was recorded and repeated for each stimulation condition 






Figure 2-1 Overview of Study a) timeline demonstrating flow of participants through 
trial. b) Experimental visit timeline. Each participant attended two identical visits 




sensitivity variance between target sites. Each stimulation period lasted 1minute, flanked 
by a 90s baseline and 180s recovery period. This is repeated 9 times, once for each 
stimulation parameter in a randomized order between subjects (orders were kept identical 
within both subject visits). See Figure 2-1b for an overview of experimental design. 
 
Ear Stimulation Targets 
This controlled study employed two different stimulation conditions (See Figure 2-2b). 
The active condition was direct electrical stimulation delivered to the inner side of the left 
tragus (anode on electrode in the outer ear canal, cathode on the surface of the tragus). 
Currently there is a debate as to optimal active stimulation position. Some groups have 
chosen to stimulate the conchae/pinna of the ear, whereas our group decided to stimulate 
the inner part of the tragus. The tragus location was chosen based on the review of 
several prior studies exploring the tragus nerve anatomy (81, 103), tragus-evoked 
potentials (104-106), auricular acupuncture trials (107, 108), and an early taVNS/fMRI 
trial (91). More generally, the hypothesis is derived from the idea that the tragus 
stimulation point is closest to the root of the ABVN and stimulation would be most 
efficient delivered there.   
 
The control condition used was the left earlobe, thought to have little auricular vagus 
nerve innervation (81). Aside from the placement, the control stimulation condition 
received identical stimulation as the active condition. This condition was included order 
to explore the hypothesized non-vagal effects of ear targets. The proximity of the earlobe 
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region serves as a very stringent control and used to model the physiological response of 
the other nerves in the ear. Subjects were not informed which condition they were getting 
or which position was thought to have greater vagal effects. 
 
Safety and Tolerability Reporting 
Participants were constantly monitored for major and minor adverse events during each 
stimulation session regardless of condition. Major adverse events were categorized as: 
extreme decreases in HR (HR) to levels less than 35BPM, respiration difficulty, and 
cardiac arrest. Minor adverse events were categorized as: skin discomfort, irritation, 
headache, facial pain, and dizziness. Procedurally, stimulation was to be aborted if the 
observing personnel noticed any adverse events (this did not occur). 
 
The participant reported pain ratings of each stimulation parameter after each stimulation 
block using a numerical rating scale (NRS) ranging from 0-10 after each of the nine 
stimulation parameters. “0” was used as the lowest rating for no sensation perceived, 
“10” was the highest pain rating for extreme intolerable pain. Participants could use 0.5 






Figure 2-2 Stimulation system and ear targets. a) taVNS was delivered using a FDA-
cleared constant current stimulator and custom stimulation electrodes. b) Schematic of 






HR Data Acquisition, Preprocessing, Statistics 
Physiological measures were recorded using a 3-channel Thought Technology system 
(Thought Technology Ltd), which measured HR using a blood volume pulse (BVP) 
sensor worn on the right index finger. BioGraph Infinity Software was used for both 
online safety monitoring as well as offline analysis. All HR data was down-sampled to 
8Hz and exported to be analyzed in IBM SPSS Statistics version 23 (IBM Corp, USA).  
 
HR was analyzed in 5-second bins. There were 12, 5s bins for stimulation period (totaling 
60s); 12, 5s bins for recovery (totaling 60s) and the baseline used was the final 5-seconds 
before stimulation started. Change scores for the stimulation period were calculated as 
the difference in HR in beats per minute (BPM) during stimulation bin and baseline. 
Change scores for the recovery period were calculated from the final stimulation 5-
second bin (bin 12). All subjects HR was blindly scanned for artifact and all subject data 
was included in the analysis (no data removed). 
 
A repeated measures ANOVA was conducted to determine the overall effect of 
stimulation condition (active vs. control) on change in HR over time throughout the entire 
time course (120s), as well as focused analysis on the stimulation period (60s) and 
recovery period (60s) independently. Secondly, individual parametric effects of HR by a 
multivariate analysis was conducted. Similar analyses were conducted for the stimulation 





Participants, Perceptual Thresholds (PT), and Stimulation Current 
15 healthy, right-handed individuals (7 female, 8 male, mean age 26.5 SD 4.99) were 
included in this study. All participants completed both visits without any dropouts. 
Perceptual thresholds (PT) varied by stimulation site and pulse width. Mean PTs (n=15) 
were as follow (mean ± SD mA): 100µs (tragus- 4.64 ± 1.28; earlobe 3.29 ± 0.92) 200µs 
(tragus- 2.66 ± 0.80; earlobe 1.82 ± 0.63) 500µs (tragus- 1.5 ± 0.46; earlobe 0.98 ± 0.35). 
Using a paired 2-tailed t-test, it was determined that tragus perceptual thresholds were 
higher than earlobe perceptual thresholds for each pulse width (p<0.01). 
 
The current at which taVNS was delivered was a scale multiplier of the PT (200%). Mean 
stimulation currents were as follow (mean ± SD mA): 100µs (tragus- 9.28 ± 2.56; earlobe 
6.57 ± 1.83) 200µs (tragus- 5.32 ± 1.60; earlobe 3.64 ± 1.26) 500µs (tragus- 3.0 ± 0.93; 
earlobe 1.97 ± 0.70). Using a paired 2-tailed t-test, it was also determined that tragus 
stimulation currents were higher than earlobe perceptual thresholds for each pulse width 
(p<0.01). Table 2-1 outlines PTs and stimulation data. 
 
Adverse Events and Pain Ratings 
There were no minor or major adverse events during the experimental sessions or 
spontaneously reported following exit of the trial. No rapidly accelerated or sustained 
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drops in HR were seen during the 1-minute stimulation periods. Minor, temporary light 
redness was seen at the sight of stimulation that disappeared within 5 minutes of 
stimulation completion. 
 
Parametric NRS scores for pain are described in table 2-2. The lowest rating a participant 
could make when they felt stimulation was a 1. For the nine various parameters, as the 
pulse width and frequency increased, as did the NRS, although the highest mean tragus 
NRS pain rating was 2.133, SD 1.34 (500µs, 25Hz) and the highest mean earlobe NRS 
pain rating was 1.23, SD .42 (100µs, 10Hz). Although some of these NRS scale ratings 
show statistical significance between stimulation conditions, the behavioral differences of 





Table 2-1: Perceptual Threshold and Stimulation Currents for Each Pulse Width Setting. 
 
 
Perceptual Threshold ± SD 
(mA) 














100µs 4.64 ± 1.28 3.28 ± 0.91 9.28 ± 2.56 6.57 ± 1.83 
Y 
(p=0.002) 
200µs 2.66 ± 0.80 1.82 ± 0.63 5.32 ± 1.60 3.64 ± 1.26 
Y 
(p=0.003) 






Table 2-2: Mean NRS Pain Ratings Reported for Each Parameter Tested. 
Parameter 








1 Hz 1.27 ± 0.59 1 ± 0 N 
10 Hz 1.67 ± 0.82 1.23 ± 0.42 N 
25 Hz 1.57 ± 0.82 1.13 ± 0.35 N 
200µs 
1 Hz 1.27 ± 0.46 1.0 ± 0.0 N 
10 Hz 1.43 ± 0.82 1.03 ± 0.13 N 
25 Hz 2.1 ± 1.36 1.33 ± 1.05 N 
500µs 
1 Hz 1.2 ± 0.56 1.07 ± 0.26 N 
10 Hz 1.77 ± 0.86 1 ± 0 Y (0.004) 




Overall Effect of Stimulation Condition on HR (HR) 
The overall pattern of effect on HR (HR) over time is illustrated in Figure 2-3. taVNS 
has very recognizable physiologic signature – when stimulation begins (stimulation 
period), HR decreases immediately and is sustained at this lower level. Upon termination 
of stimulation (recovery period), there is an immediate reorientation spike in HR that 
elevates past baseline for nearly 30 seconds which then regresses back to the mean 
resting HR. The nine different stimulation parameters each have a varied effect on HR, 
with some inducing large decreases while other parameters are less effective. 
 
To determine the overall effect of taVNS on HR, all active and all control changes in HR 
during stimulation were grouped, in 5s bins for a total of 12 consecutive bins. As 
demonstrated in figure 2-4, when all parameters are grouped together, both active 
(tragus) and control (earlobe) stimulation have a bradycardia effect, with an active mean 
HR decrease from baseline of 1.43 beats per minute (BPM), SEM 0.20, and control mean 
HR decrease of 1.02, SEM 0.20. In a repeated measures ANOVA statistical comparison, 
this effect was not significant.  
 
A repeated measures ANOVA was conducted on the one-minute post-stimulation period 
change in HR (from the final 5 second bin of stimulation).  The sympathetic rebound that 
occurs upon termination of taVNS was blunted by active stimulation compared to control 
demonstrating a condition effect of rebound spike (p<0.001).   
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Figure 2-3 Overview of mean HR changes over time for all 9 parameters. This figure 
presents the effect of both active and control stimulation on heart rate. Stimulation seems 
to have an immediate bradycardia effect during stimulation, followed by a tachycardia 









Figure 2-4 Mean change in HR over time (active v control). This figure presents the 
mean change of all 9 parameters tested in this trial, revealing a decrease in HR during 
stimulation and a recovery heart rate spike upon termination. Overall time course analysis 
reveals an overall effect of condition (P<0.001). There was non-significant effects of 
condition on the stimulation-induced bradycardia. Active stimulation had a significantly 
lower recovery heart rate spike (P<0.001). 
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The peak HR rebound was achieved during the third 5-second bin (15 seconds post-
taVNS) with a max rebound in HR for active taVNS of 8.153BPM and control 
stimulation of 11.361 BPM. The sympathetic spike time-course analysis revealed a 
significant condition*time interaction (p<0.001), as active stimulation returns to baseline 
much quicker than control stimulation.  
 
Multivariate Analysis of HR to Determine Parametric Effects 
The grouped data can subsequently be split based on specific parameters in a multivariate 
analysis. Some parameters were hypothesized to have a biologic effect whereas others 
were not. Table 2-3 shows the mean effects on HR during the stimulation period, 
separated by individual parameters. Several parameters were determined to have an effect 
of condition on the decrease of HR in the stimulation period. There were two parameters 
that had large, significant effects by condition in which active stimulation decreased HR 
more than control stimulation, and in which there was no decrease in HR in the control 
condition. These were 500µs, 25Hz (active HR -3.13BPM, control 0.799, p<0.001) and 
500µs, 10Hz (Active HR -.929 BPM, control .290, p=0.01). The HR trace during 
stimulation for these two parameters is presented in Figure 2-5.  
 
A multivariate analysis was also performed on the sympathetic reorientation spike in HR. 
Several parameters were demonstrated to suppress this sympathetic spike during the 
recovery period. These data are demonstrated in Table 2-4. The optimal parameter for  
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Table 2-3: Multivariate Analysis of Mean Change in HR from Baseline 
Parameter 
Mean Change in HR from Baseline ± 
SEM 












1 Hz -0.744 ± .781 -2.40 ± .781 0.007 N 
10 Hz -1.17 ± .0.461 -0.891 ± 0.461 0.001 N 
25 Hz 0.24 ± 0.362 0.524 ± 0.362 0.001 N 
200µs 
1 Hz 0.07 ± 0.631 -2.01 ± 0.631 0.016 Y (0.008) 
10 Hz -1.54 ± 0.353 -2.86 ± 0.353 0.021 Y (0.005) 
25 Hz -3.57 ± 0.436 -1.81 ± 0.436 0.024 Y (0.006) 
500µs 
1 Hz -2.17 ± 0.337 -0.857 ± 0.337 0.022 Y (0.006) 
10 Hz -0.93 ± 0.335 0.290 ± 0.335 0.019 Y (0.01) 




Figure 2-5 Parameters with largest bradycardia effect during stimulation. Active 
taVNS had significant parasympathetic activation compared to control in the following 
parameters (500us, 10Hz; 500us, 25Hz). 
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Table 2-4: Multivariate Analysis on Mean Change in HR for Recovery Period 
Parameter 
Mean Change in Recovery HR ± SD  












1 Hz 3.859 ± 0.998 7.296 ± 0.998 0.017 Y (0.015) 
10 Hz 1.244 ± 0.547 4.077 ± 0.547 0.038 Y (<0.001) 
25 Hz 4.348 ± 0.581 5.2 ± 0.581 0.003 N  
200µs 
1 Hz 5.436 ± 0.672 5.76 ± 0.672 0.000 N 
10 Hz 3.591 ± 0.476 4.59 ± 0.476 0.007 N 
25 Hz 2.995 ± 0.600 5.792 ± 0.600 0.031 Y (0.001) 
500µs 
1 Hz 4.512 ± 00.647 5.755 ± 00.647 0.005 N 
10 Hz 2.703 ± 0.539 4.926 ± 0.539 0.025 Y (0.004) 
25 Hz 2.644 ± 0.601 5.474 ± 0.601 0.032 Y (0.006) 
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suppression of the parasympathetic rebound based on magnitude difference of peak spike 
suppression was 100µs, 10Hz and 500µs 10Hz. 
 
Discussion 
Our analysis reveal that one-minute stimulation sessions of the left tragus is a safe form 
of neuromodulation that has no major or significant acute bradycardia effect during the 
stimulation period compared to control, although active taVNS suppresses the post-
stimulation tachycardia rebound associated with sympathetic recovery. When 
multivariate analyses were conducted, significant parameter-specific bradycardia effects 
and tachycardia suppression during and post stimulation were revealed. Conditions with 
more energy dense parameters had noticeably larger effects. Most notably, the parameters 
with highest bradycardia effects were those with higher pulse width and frequency 
(500µs 10Hz and 500µs 25Hz). The largest suppressors of the sympathetic rebound in 
HR post-stimulation were ones with 10Hz frequency (500µs, 10Hz; 100µs,10Hz) 
 
We enrolled 15 healthy individuals in this parametric feasibility and safety trial exploring 
the effects of nine various taVNS parameters of different frequencies and pulse widths. 
To our knowledge, this is the first prospective trial to systematically test the physiological 
effects of various taVNS parameters. From a feasibility and safety perspective, a taVNS 
system with custom electrodes was built for conducting laboratory studies. There were no 
minor or major adverse effects observed throughout the duration of this trial, suggesting 1 
minute taVNS periods at 200% perceptual threshold is safe and tolerable. This is very 
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similar to the safety of cervically implanted VNS (27, 33). We also determined that 
sensitivity based on perceptual thresholds varied by pulse width and stimulation location. 
As pulse width increases, less current is needed for the sensation to be perceived. The 
earlobe is significantly more sensitive (needs more current) than the tragus. The mean 
overall pain scores for active taVNS were recorded as 1.6 versus control stimulation of 
1.1. These are considered perceivable but not painful, making taVNS rather painless. 
 
Like all neuromodulation methods, the parameter space is vast and systematic parametric 
optimization trials are needed to determine optimal stimulation parameters. This trial 
suggests that individual parameters may be better than others at modulating vagal tone as 
measured by HR. Although there was no condition effect when all parameters were 
combined, there were clearly parameters that induced significant bradycardia associated 
with the parasympathetic nervous system, which is directly modulated by the vagus nerve 
(10). The more energy dense parameters caused larger decreases in HR compared to the 
lower frequency or smaller pulse width parameters. It is early to make a conclusion as to 
whether these effects are directly driven through the vagus nerve, although given the 
strict control region, these data are very encouraging. 
 
The sympathetic rebound attenuation was an unexpected finding. It has been 
demonstrated in the prior studies that this sympathetic spike in HR occurs after 
stimuli(109, 110) and is thought to be a reorienting phenomenon. It is seen 
pharmacologically as well, demonstrated in a reciprocal effect of noradrenergic blockade 
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via beta-blockers (111). The reciprocal mechanisms are intended to maintain bodily 
homeostasis and rapid activation/deactivation of stimulation of either system has a strong 
reciprocal action that occurs afterwards. This effect was measured temporally, lasting 
approximately 15 seconds to peak sympathetic rebound and final recovery to baseline at 
1minute. One prior taVNS trial suggests sympathetic nervous activity is reduced upon 
stimulation (86). It was not anticipated that active taVNS may be able to significantly 
attenuate this sympathetic rebound and it may be due to a sustained parasympathetic 
effect that persists beyond stimulation. 
 
There is a dose confound revealed in these findings, as the PT for active and control sites 
were significantly different for each of the three pulse width settings. This occurred as a 
product of trying to control for stimulation pain levels by conducting a titration based on 
sensory perception. If we had controlled for stimulation current (i.e. given everyone 
identical stimulation parameters) we would have likely seen a confound of painfulness. 
Whether the current strength that is driving the condition effect rather than the pulse 
width or frequency is still unknown, but should be acknowledged as a limitation of this 
trial. 
 
There have been several studies exploring the behavioral effects of taVNS, many of 
which are positive (78, 83, 112, 113) and prior literature has suggested that tragus 
stimulation directly modulates the vagus network via the ABVN. There have also been 
recent studies demonstrating stimulation of the ABCN has a direct effect on the afferent 
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projection of the vagus nerve, with similarities in blood oxygen level dependent (BOLD) 
as compared to cervically implanted VNS (91, 92). These fMRI findings suggest one 
possible mechanistic hypothesis for the immediate, sustained decrease in HR – 
stimulation is entering the afferent vagus system towards the central nervous system, 
activating the parasympathetic efferent cholinergic pathway targeting the viscera, 
including the heart.  
 
This field is still in its infancy and there is a lack of consensus on parameters. There is a 
wide range of currents (ranging from sub-perceptual threshold to sub-painful threshold), 
frequency (ranging from 1Hz to 299Hz), pulse width (ranging from 20us-1ms) 
stimulation duration (ranging from brief pulses to 1 minute), and type of electrical 
stimulation (constant current/voltage/direct/alternating) (91, 92, 104-108, 112). It would 
be impossible to test all various parameters, but many groups have leaned on the 
parameters used in cervically implanted VNS as a guideline.  
 
This study aimed to guide future taVNS trials in safety and HR effect of these 
parameters. It is important to determine stimulation current based on individual 
perceptual threshold, although it is still unknown as to what level (sub- or supra- 
threshold stimulation) works best. It is plausible to suggest a pulse width closer to 
chronaxie (approximately 500µs) (35) would optimally cause depolarization of nerves 
and shrink the wide range of potential parameters. And lastly, it is important to use a 
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stringent control region on the same ear of stimulation, since there appears to be a large 
physiological response due to ear lobe stimulation alone. 
 
Limitations 
We acknowledge that a sample size of 15 individuals may not be large enough to truly 
determine which parameters modulate HR the best. This initial trial was developed as a 
safety and feasibility trial, with the secondary effects of HR to be explored, as the 
parameter space was quite large. Larger controlled trials should further explore some of 
the parameters here that are suggested to be more optimal in modulating HR.  
 
Secondly, it is impossible to truly say these outcomes are as a direct effect of stimulating 
the ABVN as the only way to definitively say that would require dissection and direct 
nerve stimulation. Based on prior literature and anatomical trials (81), we believe that 
stimulation of the tragus is directly stimulating the ABVN, whereas the earlobe has little 
to no ABVN innervation, and therefore less parasympathetic derived effects. 
 
Lastly, we concede it is still unknown whether the effects seen are through the 
hypothesized afferent central targets of the vagus system (ear –> brain –> vagus -> body), 
or whether they are modulating parasympathetic response via direct efferent projections 
from the ear to the periphery (ear -> vagus -> heart). This is difficult to determine without 
systematic, parametric testing using combined taVNS and neuroimaging paradigms or 
with in-vivo microelectrode recording of nerve dissections in animal models. 
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Conclusion 
taVNS administered for 1 minute at 200% perceptual threshold in these nine parameters 
is a feasible and safe neuromodulator technique. No significant adverse events were 
observed and overall, both active and control stimulation result in a minor bradycardia 
during stimulation, whereas active stimulation suppressed the sympathetic reciprocal 
effect post-stimulation. Further parametric exploration must be conducted to determine 






STUDY 2: DETERMINING THE OPTIMAL taVNS PARAMTER WHICH 
ACTIVATES THE PARASYMPATHETIC NERVOUS SYSTEM  
 
Study Summary  
Background: An initial exploratory study conducted by our team (described in Chapter 
2) investigated the effects of nine various taVNS parameters on HR and determined two 
optimal parameters which most likely activated the parasympathetic nervous system. This 
study follows-up on this initial trial by testing the winning parameters against each other 
and against control. 
 
Objective:  Determine which of the following parameters (500µs 10Hz or 500µs 25Hz) 
optimally activate the parasympathetic nervous system compared to control stimulation.  
 
Methods: We enrolled 20 healthy individuals in a 2-visit follow-up trial exploring the 
HR effects of the two parameters optimally modulating HR determined by trial 1. 
Individuals attended two separate experimental visits (active, control) and received 10 
sessions of 1-minute taVNS, flanked by a 60 second baseline and 90 second recovery 
period. HR was monitored continually throughout each experimental visit. Statistical 
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analysis was conducted on overall effect of condition (both parameters combined; active 
vs control) for the entire time course (120s) as well as a focused analysis on the 
independent stimulation period (60s) and recovery period (60s). Specific parametric 
analysis on each discrete parameter was conducted exploring the overall individual 
parameter effects (active vs control) similar to the method for all paramters.   
 
Results: Active taVNS significantly decreased HR compared to control during 
stimulation (p=0.02). taVNS did not affect recovery sympathetic spikes as control and 
active stimulation had similar magnitude reorientation increases in HR. The overall effect 
was primarily driven by the strong bradycardia effect induced in the 500µs 10Hz 
parameter (p=0.032) although both active parameters decreased HR compared to control. 
 
Conclusion: This confirmatory follow-up study determined that the optimal parameter to 
modulate the parasympathetic response activated via direct electrical stimulation of the 
auricular branch of the vagus nerve (ABVN) was 500µs, 10Hz. Both active parameters 
induced bradycardia compared to control, suggesting taVNS activates the 
parasympathetic nervous system. 
 
Introduction 
Study Aim 1 Findings  
Chapter 2 of this dissertation described an initial parametric study we conducted in 15 
healthy individuals. The goal of this first trial was three-fold. Initially, when developing a 
60 
novel form of neuromodulation, it is important to establish the safety profile of the 
method, as well as appease concerns of the MUSC IRB concerning participant safety. In 
2014 when these trials were conceptually started, the literature was very sparse and 
MUSC had not conducted a prior taVNS study. There also was no system to administer 
it, so Bashar Badran (with the help of Alan Badran) developed stimulating electrodes 
targeting the requisite ear targets.  
 
Secondly, the trial was aimed at determining whether there were parameter-specific 
effects of taVNS on HR. More precisely, we aimed to determine whether longer pulse 
widths and higher frequencies (more energy per pulse) would result in larger decreases in 
HR via the parasympathetic nervous system. Prior cervically implanted VNS/fMRI trials 
conducted by Nahas et al (51) demonstrated increased blood oxygen level dependent 
(BOLD) signal activation in the brain as the pulse width was serially increased from 
130us to 500us. Before conducting studies in the MRI scanner with our taVNS system, 
we aimed to use HR as a surrogate marker of parasympathetic activity and show 
increased effects with higher pulse widths and frequencies.  
 
Our final goal was to determine which of the nine parameters were optimal in modulating 
the parasympathetic system. We analyzed this data and compiled the measures to give us 
an overall perspective on optimal parameters. The effect size of the repeated measures 
ANOVA as well as whether there was a control effect were both unutilized in making the 
ultimate decision that 500us 10Hz and 500us 25Hz parameters optimal parameters at 
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modulating parasympathetic nervous system activity. The findings of the first study 
determined that taVNS was feasible, safe, and identified optimal parameters of the initial 
nine exploratory parameters.  
 
Rationale Behind Study 2 
This follow-up study aimed to be a confirmatory study on the parameters hypothesized to 
optimally modulate the parasympathetic nervous system. To do this, the best two 
parameters from study 1 (500µs 10Hz & 500µs 25Hz) were tested against each other and 
against control stimulation (earlobe). To positively determine this, the number of 
participants was increased to 20 for this follow-up trial and also increased the number of 
times the parameter was tested (five stimulation runs for each parameter, 10 total), unlike 
trial 1 which had only one stimulation run for each of the 9 parameters. We hypothesized 
that by making these changes, active taVNS will have a significant effect on HR during 
stimulation. More specifically active taVNS will induce bradycardia during stimulation 
as modulated by the parasympathetic nervous system activation that occurs. Given the 
nerve innervation of the human auricle (81), control stimulation should have minimal 
effect on activating the parasympathetic nervous system. 
Methods 
Overview 
This follow-up study is resembles and is nearly identical to the design of the first HR 
study described in Chapter 2. This study conducted was a 2-visit, controlled, crossover 
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trial. Individuals came to the Medical University of South Carolina (MUSC) brain 
stimulation laboratory for two separate 45 minute experimental visits (active/control 
visits, counterbalanced design) (Figure 3-1a). Each visit was identical except for 
stimulation condition. This study was approved by the MUSC Institutional Review Board 
(IRB) and is registered on ClinicalTrials.org (NCT02835885). 
 
Although similar to the study described in Chapter 2, there are several important major 
changes that differentiate this study from the prior study. The reader should draw their 
attention to the following differences: 
 
1. Only 2 parameters are explored in this trial (500us 10Hz, 500us, 25Hz). 
See introduction for the rationale. 
2. 10 stimulation rounds were administered each visit (5 for each parameter). 
This differs from study 1 in which each parameter was tested only once. 
This is intended to increase the power for statistical analysis.  
3. Biopac System was used for Heart Rate using 2-channel 
electrocardiogram (ECG) rather than BVP as used in the Thought 
Technology system from study 1. 
4. Methods that are repeated in this section will be indicated to refer reader 
back to the appropriate section of Chapter 2 to avoid repeating general 
methodology. 
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Participants and Inclusion Criteria 
We enrolled 20 healthy adults (10 female) in this trial after meeting the same inclusion 
criteria listed in Chapter 2 (See Chapter 2, Methods for detailed description). 
 
taVNS Stimulation System  
We used the same stimulation system developed for the initial HR study described in the 
previous chapter. (See Chapter 2, Methods for detailed description and figure.)  
 
taVNS Stimulation Paradigm & Parameters 
Participants lay supine with their neck and head elevated in a comfortable position with a 
pillow. They were instructed to stay awake and maintain a still, comfortable position. 
Stimulation targets were prepped with alcohol swabs (70% isopropyl alcohol) to clean 
surface oils and decrease skin resistance. 
 
Stimulation parameters of either 500µs 10Hz or 500µs 25Hz were used. Parameters were 
randomized and counterbalanced over each of the 10 rounds (5 rounds of each 
parameter). These parameters were chosen as the most likely candidates to best modulate 
heart rate from trial 1. Similarly to trial 1, the stimulation current (mA) was delivered at 
200% of each participant’s individual perceptual threshold (PT) of a 500µs pulse width.  
Each stimulation period lasted 1minute, flanked by a 60 second baseline and 90s recovery 






Figure 3-1 Overview of Study a) timeline demonstrating flow of participants through 
trial. b) Experimental visit timeline. Each participant attended two identical visits 
structured as presented in the figure.  
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order between subjects (orders were kept identical within both subject visits). See Figure 
3-1b for an overview of experimental design. 
 
Ear Stimulation Targets 
This controlled trial employed identical stimulation sites on the left ear. Active taVNS 
was delivered to the left tragus, control stimulation to the left earlobe. For a detailed 
description and figure of these sites, refer to Chapter 2, Methods, Ear Stimulation 
Targets).  
 
Safety and Tolerability Reporting 
Participants were constantly monitored for major and minor adverse events during each 
stimulation session regardless of condition and were asked to report pain ratings at the 
completion of each of the ten stimulation periods using a NRS. For a detailed description 
of safety criteria and NRS refer to Chapter 2, Methods). 
 
HR Data Acquisition, Preprocessing, Statistics 
Physiological measures were recorded using a 2-channel Biopac ECG system (Biopac 
Systems Inc., USA), which measured HR using electrocardiogram electrodes attached to 
the subject’s chest. AcqKnowledge 4.1 software was used for both online safety 
monitoring as well as offline analysis. All HR was consolidated into 5sec epoch bins and 
exported for analysis in IBM SPSS Statistics version 23 (IBM Corp, USA).  
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HR was scanned for usability, and participant 20 of this study reported excessive artifact 
in stimulation round C of the control visit, which was excluded from analysis. The 
remaining 9 stimulation rounds for this participant were kept in the analysis. 
 
HR was analyzed in 5-second bins. There were 12 bins for stimulation period (totaling 
60s); 12 bins for recovery (totaling 60s). The baseline used was the final 5-seconds 
before stimulation started. Change scores for the stimulation period were calculated as 
the difference in HR in beats per minute (BPM) during stimulation bin and baseline. 
Change scores for the recovery period were calculated from the final stimulation 5-
second bin (bin 12).  
 
A repeated measures ANOVA was conducted to determine the overall effect of 
stimulation condition (active vs. control) on change in HR over time throughout the entire 
time course (120s), as well as focused analysis on the stimulation period (60s) and 
recovery period (60s) independently. Secondly, individual parametric effects of HR by a 
multivariate analysis was conducted. Similar analyses were conducted for the stimulation 





Participants, Perceptual Thresholds (PT), and Stimulation Current 
20 healthy, right-handed individuals (10 female, 10 male, mean age 25.65 SD 5.53) were 
included in this study. All participants completed both visits without any dropouts. Mean 
perceptual thresholds (PT) are as follow (mean ± SD mA): 500µs (tragus- 1.045 ± 0.49; 
earlobe 1.02 ± 0.41). The current at which taVNS was delivered was again a scale 
multiplier of the PT (200%). Mean stimulation currents were as follow (mean ± SD mA): 
500µs (tragus- 2.09 ± 0.97; earlobe 2.04 ± 0.82).  Using a paired 2-tailed t-test, it was 
determined that there was no difference in perceptual threshold between the two 
stimulation sites. Table 1 outlines mean PTs and stimulation data for all subjects. 
 
Adverse Events and Pain Ratings 
Similar to experiment one, there were no minor or major adverse events during 
experiment two. The Mean NRS scores for pain are described in table 3-1, and although 
there was a significant difference in pain between parametric-specific stimulation targets 
when analyzed using a paired t-test, these are not reflective of the minimal pain reflected 
in the ratings (mean pain difference between conditions less than one rating point, max 




Effect of Stimulation Condition on HR (HR) 
Experiment two successfully demonstrated replication of the physiological response to 
taVNS. As stimulation starts, there is an immediate bradycardia observed that persists 
throughout the entire stimulation period. Upon termination of stimulation tachycardia 
occurs for approximately 30s. The overall effect on HR over the 120-second period is not 
statistically significant. Figure 3-2 shows the time course analysis of mean changes from 
baseline in the stimulation and recovery periods of all active vs. all control stimulation 
rounds.  
 
To determine the effect of taVNS on HR during the stimulation period, the 60s 
stimulation period was analyzed by condition in a repeated measures ANOVA and 
demonstrates a strong active taVNS effect on bradycardia (P<0.02). Active taVNS 
produced a mean decrease in HR of 1.82 ± 0.174 (SD), whereas control stimulation only 
decreased a mean of 1.2BPM ± 0.178 (SD). A repeated measures ANOVA was also 













PT ± SD (mA) 1.045 ± 0.48 1.02 ± 0.41 
N Stim. Current ± 
SD (mA) 2.09 ± 0.97 2.04 ± 0.82 
Mean 500us 10Hz 
NRS Pain Rating 
± SD 1.35 ± 0.68 2.24 ± 1.28 Y (P<0.01) 
Mean 500us 25Hz 
NRS Pain Rating 





Figure 3-2 Mean change in HR over time (active v control). This figure presents the 
mean change of all both parameters tested in this trial. Active taVNS induces significant 
decrease in HR during stimulation (p=0.02), although the recovery HR spike upon 




Parameter-Specific Effects on HR 
The grouped data can subsequently be split into 500µs, 10Hz and 500µs 25Hz 
parameters. Exploring the significant effect of bradycardia in the stimulation period in the 
overall analysis, a repeated measures ANOVA was conducted on the stimulation period 
by parameter, and the results are highlighted in Figure 3-3. Active taVNS at 500µs, 10Hz 
induces a significant bradycardia effect sustained throughout the entire stimulation period 
(P=0.032). Mean decrease for the active condition was -2.40BPM ± 0.275 vs. control, 
which only produced a -1.56BPM ± 0.275 change from baseline (Table 3-2). The 500µs 




We enrolled 20 healthy individuals in this follow-up, confirmatory study aimed to 
determine the optimal taVNS parameter modulating parasympathetic nervous system 
activity. When compared against control stimulation, active taVNS significantly 
decreased HR, a surrogate marker of parasympathetic nervous system activity. When 
analyzed by parameter, 500µs 10Hz had the greatest effect on HR during the stimulation 
period. A prior taVNS trial suggested sympathetic nervous activity is reduced upon 
stimulation (86) and is briefly mentioned in Chapter 2. That study used a smaller pulse 
width, but higher frequency (200µs 30Hz). Whether the mechanism is the direct decrease 





Figure 3-3 Parametric effects on bradycardia. a) Overall effect of active taVNS 
compared to control (p=0.02). b-c) Active taVNS at 500us 10Hz has a significant effect 
on HR (p=0.032) when compared to control whereas 500us 25Hz is not statistically 
different.
Overall Bradycardia Effect  
500us, 10Hz bradycardia 
effect 






Table 3-2: Mean Decrease in HR During Stimulation Period (By Parameter) 
Parameter 
Mean Change in HR from Baseline ± 
SEM 












10 Hz -2.40 ± 0.275. -1.56 ± 0.275  0.01 Y 
(P=0.032) 





Unlike the initial nine-parameter trial described in Chapter 2, which demonstrated an 
attenuation of the sympathetic rebound in HR in the recovery period, this effect was not 
demonstrated in this study in either the overall or parametric study analysis. Both active 
and control stimulations had similar spikes in HR upon termination of stimulation that 
occurs as a described in the healthy functioning of the autonomic nervous system(109, 
110). It is suspected that the reciprocal sympathetic spike in heart rate counteracts the 
parasympathetic activation via active taVNS, although in this trial, the active stimulation 
effect was much larger than the first trial, possibly causing a higher magnitude reciprocal 
spike. This directly contradicts the initial hypothesis generated from Study 1 in which it 
was believed there was a persisting parasympathetic activation that blunts the 
sympathetic spike. It is impossible to say that this is definitively what is occurring and 
future studies should be designed to directly focus on this balance between rapid 
sympathetic/parasympathetic activation.  
 
The many trials exploring the positive neuropsychiatric effects of taVNS (78, 83, 112, 
113) could not possible if taVNS had primarily an efferent parasympathetic effect. It 
must be due to increasing parasympathetic or decreasing sympathetic nervous system 
activity as modulated centrally in either cortical or subcortical brain structure. Recent 
fMRI trials seem to confirm this hypothesis (91, 92). One can reasonably conclude that 
taVNS has both afferent and efferent vagal effects although whether the modulation of 
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heart rate is directly efferent or whether the heart rate effect is due to a short loop traveled 
by the signal to the central hypothalamic cholinergic pathway is still to be determined. 
 
It is unknown as to which is more important – pulse width or frequency. There is a 
lacking of data in the recent taVNS trials to answer such a question. The various 
behavioral effects are derived from many various pulse widths, frequencies and 
stimulation currents. (91, 92, 104-108, 112). This trial confirms that a pulse width of 
500µs at both 10Hz and 25Hz, when combined, give an overall effect of bradycardia 
during stimulation and that the 10Hz parameter, when compared to control, induced a 
larger effect on HR. It is suspected that pulse width is more important than firing 
frequency, as that is required for neuronal depolarization near the nerve chronaxie levels 
(35) causing depolarization and signal transduction.  
 
The bradycardia associated with control stimulation was again seen in this study, 
similarly in effect and magnitude to trial 1. A responsive control site is important to 
investigate the active site of stimulation with rigor, although it is plausible that there may 
be some transduction of electrical signal into superficial branches of the ABVN. Nerves 
are often branched and act as electrical conductors. It is highly plausible that there is 
some transduction of electricity from the earlobe to distal branches of the ABVN that 
may be spatially proximal to the site of stimulation. Even with stringent controls, the 
parasympathetic effect of taVNS is significant, demonstrating that less than 3 cm of 




This follow-up study confirms that electrical stimulation of the a ABVN via taVNS at 
500µs 10Hz is the optimal parameter for activating the parasympathetic nervous system 
and decreasing heart rate in healthy individuals. No significant adverse events were 
observed and overall. Active taVNS in an overall analysis demonstrated significant 
bradycardia during the stimulation period. This serves as a strong foundation that 
stimulation of the ABVN can induce efferent autonomic nervous system responses that 
can be measured using physiological recordings. It is important to conduct neuroimaging 
trails further exploring the central effect of taVNS to determine whether there are 




Synthesis of Experiments One and Two 
The two prior experiments described are important both practically and conceptually. 
There is an ever-present push to drive therapeutics rapidly towards treating various 
disorders, whether central or peripheral. This rush introduces a high risk of failure, or the 
early dismissal of a therapy that may have a biologic effect if parametrically tested for 
optimal administration. 
 
In the case of electrical stimulation, there are a variety of different parameter 
combinations that may have a biologic effect. This series of studies demonstrates 1) pulse 
77 
width matters. The higher the pulse width, the stronger of an effect described in the initial 
parametric trial. 2) Higher frequencies are not always better. 10Hz outperformed 25Hz in 
the follow-up confirmatory trial. 3) taVNS does have a biologic effect that seems to be 
driven through the vagus nerve.  
 
The final confirmatory step to determine if taVNS has a direct brain effect or whether 
these are just peripheral vagal responses is to conduct a concurrent taVNS imaging trial 
exploring the brains response to stimulation. This was the third aim of the dissertation 






STUDY 3: USING CONCURRENT taVNS/fMRI TO DETERMINE THE DIRECT 
BRAIN EFFECTS of taVNS  
Study Summary  
Background: Although there are numerous trials involving stimulating the auricular 
branch of the vagus nerve (ABVN), the exact brain regions activated are poorly 
understood. Electrical stimulation of the ABVN via transcutaneous auricular vagus nerve 
stimulation (taVNS) likely targets vagal afferent networks and is the theorized 
mechanism for taVNS. 
 
Objective: We developed a concurrent taVNS/fMRI system to determine the direct brain 
effects of taVNS compared against control stimulation. 
 
Methods: We enrolled 17 individuals in the two-visit controlled, crossover trial. 
Individuals attended two scanning visits in which they received taVNS at 500µs 25HZ 
delivered to either their left earlobe (control) or tragus (active). Whole brain analysis was 
performed using SPM 12 exploring the effect of the following groups: control stimulation 
only, active stimulation only, active>control, active <control (FWE corrected P<0.05). 
An ROI analysis was conducted on the midbrain and brainstem regions of all groups.  
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Results: Earlobe (control) stimulation produces BOLD signal activation in the 
contralateral somatosensory representation of the face region, whereas tragus (active) 
stimulation produces significant activations in the contralateral postcentral gyrus, 
bilateral insula, frontal cortex, right operculum, and left cerebellum. In the active vs. 
control contrast, active stimulation produces significant activations in the right caudate, 
bilateral anterior cingulate, cerebellum, left prefrontal cortex, and mid-cingulate. 
 
Conclusion: These findings reveal the afferent projection of taVNS delivered to the 
tragus produces cortical and subcortical effects in regions of the brain known to be part of 
the afferent vagal pathway. 
 
Introduction 
Modern functional neuroimaging methods can be used to measure the neurophysiological 
effects of a stimulus or intervention. The most common of these methods are 
electroencephalography (EEG), positron emission tomography (PET), and functional 
magnetic imaging (fMRI). Each technique has its benefits and drawbacks. EEG has an 
extremely high temporal resolution on the scale of milliseconds and is great for capturing 
fast neuronal propagations, although it lacks spatial resolution and deductions can only 
reliably be made regarding cortical activity. PET and fMRI are similar as they both 
indirectly measure brain activity, although PET has a much lower imaging resolution 
than fMRI, uses radioactive isotopes, and is more expensive.  
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fMRI images the blood oxygen level dependent (BOLD) signal in the brain, which is 
considered and utilized as an indirect marker of neural activity (47). The BOLD signal 
measures the temporal changes of oxyhemoglobin and deoxyhemoglobin. As neuronal 
depolarization occurs, oxygen is consumed and increased blood flow is delivered to 
higher metabolism areas, bringing with it oxyhemoglobin, producing a stronger MR 
signal than its deoxygenated counterpart. It is this difference in magnetism is exploited in 
the fMRI method. In short, increased oxyhemoglobin is believed to reflect increased 
neuronal activation. 
 
taVNS/fMRI Potential Roadblocks and Solutions 
In order to successfully conduct these multimodal imaging trials in which stimulation 
electrodes like those used in cervically implanted VNS and taVNS and conductive wires 
are either implanted or externally placed in the magnetic field of the scanner, the 
following potential issues need to be considered: 
 
1. Induced electrical current in the wire 
In 1831, Michael Faraday (114) demonstrated the law of induction. Faraday’s law states 
that electrical current is produced in conductive materials placed in or around a magnetic 
field. Electromagnetic induction is used in power generation and transmission and is used 
immensely in modern electronics. We also can reference Faraday’s law for how 
transcranial magnetic stimulation (TMS) works (115) in stimulating the brain.  
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Unfortunately, induction poses a problem when placing conductive materials in the MRI 
scanner. The static and dynamic magnetic field of the scanner introduces the risk of 
inducing unwanted electrical current in the wire.  
 
To circumvent these induced fields, resistors (5kΩ) of sufficient size must be placed in 
the lead wires of the electrode to block these currents while simultaneously being able to 
be surmounted by the power of the driving electrical stimulator. Without controlling for 
induced currents, unwanted stimulation of target sites may occur without intent or 
knowledge.  
 
2. Electrode Heating 
A potential safety concern of electrodes attached to the end of long wires placed in the 
MRI is the risk of heating these electrodes due to the interaction of the radio frequency 
(RF) electromagnetic field (116-119). This heating occurs at the end of the wire or 
electrode and can cause burns to the stimulation site, or even permanent irreversible 
damage if the electrodes are implanted in the case of VNS or deep brain stimulation 
(DBS) (49, 120). For this reason, sufficient testing must be conducted to determine safety 
of these paradigms.  
 
Although there is no direct solution to this problem, special head coils for the fMRI 
image acquisition can be used in order to minimize the RF electromagnetic field and 
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minimize heating. The resistors placed in the lead wires also reduce the heating. It is 
important to ensure the conductive medium (e.g. gel, paste) used for stimulation can 
withstand heating without degrading.  
 
3. MRI Artifact 
Wires delivering electrical stimulation from outside the magnet room of the scanner 
(equipment room or control room) introduce RF into the scanner. The wire becomes a 
large antenna that may produce an RF overflow artifact causing a non-uniform 
appearance in part of the image or even the entire image. In order to minimize this 
artifact issue, any externally driven stimulation needs to be delivered through an RF filter 
and grounded to a panel so that the fMRI signal does not become distorted. 
 
The prior three concerns were all addressed before conducting the final study described 
in this chapter. All developmental experimentation was conducted on MRI phantoms in 
order to optimize stimulation feasibility as well as reduce artifact and heating and ensures 
safety. Three pilot scans on healthy individuals were also conducted following phantom 
trials, those individuals were used for optimization of the taVNS method and were not 
enrolled into the prospective taVNS/fMRI trial. 
 
Prior taVNS/fMRI Trials 
There have been five imaging trials specifically designed to determine the afferent 
pathway of taVNS. The first taVNS/fMRI trial was conducted in 2007 by Kraus and 
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colleagues (91). They used fMRI to image 22 healthy individuals and aimed to determine 
whether stimulating the left tragus (active) or earlobe (control) at 20µs and 8 Hz for (30s 
ON, 60s OFF) produced short-term brain activations in a crossover design. Active 
stimulation produced decreases in limbic brain areas, including the amygdala, 
hippocampus, parahippocampal gyrus and the middle and superior temporal gyrus. They 
also demonstrated increased activation in the insula, precentral gyrus and the 
thalamus. Control stimulation revealed no significant BOLD responses in either direction. 
No brainstem activation was reported in either condition.  
 
This same group conducted a follow-up trial in 16 healthy individuals exploring regional 
specificity of the induced BOLD response from taVNS. This study stimulated either the 
left auditory canal (8 subjects receiving anterior tragus stimulation, 8 subjects receiving 
posterior auditory ear canal stimulation) or the earlobe (all 16 subjects) in a crossover 
design. Stimulation parameters were identical to their prior trial (20µs and 8 Hz for 30s 
ON, 60s OFF). The results of the study are in line with their previous fMRI studies (92),  
showing robust BOLD signal decreases in limbic structures and the brain stem during as 
well as BOLD activation in frontal and insular cortex via electrical stimulation of the left 
anterior auditory canal. Interestingly, stimulation at the posterior wall seems to lead to 
unspecific changes of the BOLD signal within the brainstem and vagal afferent 
projections. Earlobe control stimulation again produced no major significant BOLD 
signal responses. This study suggests the anterior auditory canal (tragus) to be a much 
more effective ABVN target than the posterior wall.  
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In 2008, a very small taVNS trial was conducted by Dietrich and colleagues in four 
healthy males. The goal of this study was to test new parameter settings and a novel 
device they have developed. This open-label single arm (active only) study delivered 50s 
blocks of taVNS (250µs, 25HZ) to the left tragus. They authors suggest that taVNS 
induced increases in BOLD signal in the thalamus, prefrontal cortex and brainstem (90) 
although this was not described in any of the other four trials. This study is considered 
very inconclusive as it lacks effective control and based on the small sample size, but 
merits further exploration of the parameters employed. 
 
In 2015, Frangos et al (93) conducted a taVNS/fMRI trial exploring the regional effects 
of electrical stimulation of two stimulation sites (cymba conchae vs. earlobe control; 
crossover design) in 12 healthy individuals. The stimulation parameters were 250µs, 
25Hz, for one stimulation ON block lasting 7minutes. Their findings reveal conchae 
stimulation, compared to earlobe (control) stimulation, produced significant activation of 
vagal afferents, most notably the ipsilateral NTS, locus coeruleus (LC), dorsal raphe, 
amygdala, and nucleus accumbens. Findings also demonstrate deactivations in the 
hypothalamus and hippocampus. This trial differs from prior trials as the stimulation 
duration is highly unconventional and longer than any of the prior behavioral or imaging 
trials (7min stimulation of target sites with only one block each). No forebrain findings 
were discovered and imaging the deep mid brain and brain stem activation validity are 
still debated amongst imaging experts. 
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The most recent taVNS/fMRI trials were conducted by Yakunina et al. in 2016. This 
study explored brainstem activations (NTS and LC) of four different stimulation sites on 
the ear (inner tragus, posterior wall of ear canal, cymba conchae, earlobe control). Not 
only did it have the most stimulation sites of any study, it also recruited the highest 
number of subjects of any prior taVNS trial (37 healthy individuals)(89). Stimulation was 
delivered at 500µs, 25Hz for 6min ON blocks. Both earlobe and posterior ear canal 
stimulation sites produced the weakest NTS and LC activation, whereas the tragus and 
concha targets produced robust brainstem (vagal mediate) activations. When tested head 
to head, the concha was revealed to be the optimal stimulation site to activate the NTS 
and LC. This study suggests the concha may be a better target than the tragus. 
 
It is important to note that all fMRI trials have widely varied methodology. They employ 
different stimulation parameters, stimulation durations, and whether a control was used or 
not. These studies, their differences and findings are summarized in table 4-1. The field 
of taVNS still lacks a consensus on many of these stimulation targets are highly debated 
within the small field. 
 
Study Introduction and Hypothesis 
Prior studies described in Chapters 2 and 3 of this dissertation attempted to determine 
whether optimal taVNS parameters could be discovered using parasympathetic decreases 
in HR as measures. Although it was determined that larger pulse widths and higher 
frequencies of parameters modulate the parasympathetic response greater than lower 
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parameters and control, it is still unknown whether taVNS has a direct effect on the 
afferent vagal pathway of the central nervous system.  It has been suggested via fMRI 
studies that stimulation of the ABVN  has afferent brain effects that are initiated via the 
brainstem (89, 93) although there have been no neck dissection studies looking at the 
connection of the ABVN to the main bundle or the brainstem. There is mixed, limited 
fMRI data on the afferent effects of taVNS, with studies varying in stimulation duration 
and parameter. 
 
One of the optimal parameter candidates from the initial physiological trials described in 
Chapter 2 was used to explore the direct brain effects of taVNS using concurrent 
taVNS/fMRI. We hypothesize that by using parameters known to have a biologic effect 
in our prior trials relevant and significant brain activation changes in afferent vagal 




We conducted a 2-visit, single blind, sham-controlled, crossover fMRI trial exploring the 
effects of active taVNS stimulation compared to earlobe stimulation (control). 
Participants attended 2 scanning visits, separated by at least 1 day apart to avoid any 
carryover effect. All scanning was conducted at the MUSC Center for Biomedical 
Imaging 30 Bee Street location. This study was approved by the MUSC Institutional 
Review Board (IRB) and is registered on ClinicalTrials.org (NCT02835885). 
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Participants and Inclusion Criteria 
17 healthy individuals (8 female) were enrolled after meeting the following inclusion 
criteria: age 18-45, no personal or family history of seizure, mood, or cardiovascular 
disorders, no facial or ear pain, no recent ear trauma, no metal implants including 
pacemakers, not pregnant, no dependence on alcohol or recent illicit drug use, not on any 
pharmacological agents known to increase seizure risk (Bupropion, neuroleptics, 
albuterol, theophylline, antidepressants, thyroid medications, or stimulants). Participants 
were screened for MRI exclusionary criteria as well (metal in body and claustrophobia).  
 
fMRI Scanning 
All MRI scanning was conducted using a Siemens TIM Trio 3.0T system and the 
provided Siemens 32-Channel head coil. Individuals were positioned head-first supine on 
the bed of the scanner and foam pads were used to stabilize the head and minimize 
movement.  
 
Each of the two visits lasted approximately 30-minutes in duration during which 3 
functional sessions were acquired (Figure 4-1a). Following a localizer scan, a high 
resolution anatomical MPRAGE (TR: 1900ms; TE: 2.26ms; Voxel size: 1mm3; 208 
slices, FA: 9 deg) was collected. Following the anatomical image, three separate 
functional scans were acquired, in which subjects received (either active or sham) 
concurrent taVNS. The order of active and sham stimulation was counterbalanced.   
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 Figure 4-1 Imaging study design. a) Overview of scanning visits and MRI scans 
acquired. b) Block design of the concurrent taVNS/fMRI BOLD scans with time on and 






Lastly, a field map was acquired to correct for distortions due to magnetic field 
inhomogeneity.  
 
The concurrent taVNS/fMRI scans were conducted using an echo-planar imaging (EPI) 
sequence (TR: 2800ms; 126 volumes, TA: 5:52s, TE: 35ms; Voxel size: 3.0mm3; 47 
slices, FA: 76 deg), with a block design (Figure 4-1b). Each scan run was identical, 
consisting of an initial 30s “OFF” period with no stimulation, followed by 3, 60s “ON” 
periods in which electrical stimulation was delivered to the ear. The time between “ON” 
periods was 60s, followed by a final 22s “OFF” period after the final stimulation block. 
Each functional session lasted 6 minutes. The stimulation was synchronized with the start 
of each taVNS/fMRI BOLD sequence acquisition (from 0:00 and ran to 5:52 for each 
taVNS/fMRI run) and was triggered upon first fMRI volume acquisition in the equipment 
room using an automated stimulation system that delivered TTL pulses to the constant 
current stimulator at specific frequency and duration. Timing validation was confirmed 
with the console timer after each individual stimulation session. Upon completion of each 
taVNS/fMRI scan, individuals were asked through intercom how many stimulation 
blocks they felt in order to verify signal transmission into the scanner and all three “ON” 
blocks were delivered. They were also asked to rate their pain on a NRS from 1 (no pain) 
-10 (extreme pain) 
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Concurrent taVNS/fMRI System 
Stimulation was delivered via custom developed stimulating electrodes pictured in 
Figure 4-2a. Computer assisted drawings of the electrode clamps (Figure 4-2b) were 
generated in SketchUp (Timble Navigation, USA) and subsequently 3D printed out of 
ABS plastic at the MUSC Brain Stimulation Laboratory (Flashforge Creator Pro, China). 
The round, unipolar stimulation electrodes were 1cm in diameter made of Ag/AgCl and 
affixed to the 3D printed clamps using cyanoacrylate. Copper was used for all wiring. 
Ten20 conductive paste was used as a conductor for the electrodes. 
 
Constant current stimulation was delivered using a Digitimer DS7a set to <400V. Lead 
wires were attached to the Digitimer output and connected to a radio frequency (RF) 
patch panel in the wall between the equipment room and magnet room using a serial 
connector on both sides. Figure 4-3 demonstrates the taVNS/fMRI setup visually. Wire 
was run from the patch panel in the magnet room towards the foot of the MRI scanner, 
where it was then run on top of the participant who was laying supine head first on the 
scanning table. ½ inch PVC piping was used to insulate the wires and rested on the 
participant’s abdomen and the stimulation electrodes were clamped to the individual’s 
tragus or earlobe depending on condition. 
 
taVNS Parameters and Stimulation Targets 
The parameters used for this fMRI trial were 500µs 25Hz (monophasic square waves) 
based on previous autonomic effects described in Chapters 2 and 3 of this   
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Figure 4-2 fMRI compatible electrodes a) picture of final taVNS electrodes that have 
been 3d printed and assembled b) CAD drawings of electrodes demonstrating the 3-piece 
design and “U” shaped spring clip. Ag/AgCl electrodes were affixed to the inside part of 




Figure 4-3 taVNS/fMRI Setup. This figure shows how taVNS is synchronized and 
delivered to the scanner. Timing is driven off the control room main console computer. 
Triggering of the direct current stimulator occurs in the equipment room which 
propagates an electrical stimulation current through a grounded RF filter and into the 
magnet room through a 10m cable that attaches to the participant’s ear in the scanner. 
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dissertation. Stimulation current was set to 200% of perceptual threshold (PT) and the PT 
was determined while the subject had electrodes attached and was lying in the scanner. 
Perception of stimulation was relayed to the equipment room via intercom and the current 
modified until the participant felt the minimum perceptual level. Active stimulation was 
delivered to the left tragus, control stimulation to the left earlobe (Figure 4-1c). 
Data Processing and Analysis 
All images were converted from DICOM to NifTI using dcm2nii program. All further 
processing and analysis was performed in SPM 12 software (UCL) using MATLAB 
R2012a (The MathWorks Inc, Natick, MA). First, deformations required for 
normalization were derived from whole brain anatomical images using Segment. Skull 
stripped anatomical images were created from grey matter, white matter and CSF masks 
with Image Calculator to improve functional to anatomical coregistration. Next, the 
functional images were processed through Realign and Unwarp to reduce motion related 
variance and correct distortions due to magnetic field inhomogeneities. The mean image 
from realignment was coregistered to the skull stripped anatomical image using a 
normalized mutual information algorithm. The estimated coregistration parameters were 
combined with the forward deformations applied to the functional data in a single step to 
bring the data into MNI space. Finally, the data was smoothed using an 8mm FWHM 
Gaussian smoothing kernel. Estimated movement parameters were examined and no 
participants exceeded our movement threshold of one voxel.  
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For subject level general linear modeling, the three stimulation “ON” periods (onset 
times: 30s, 150s, 270s; duration 60s) were convolved with the canonical hemodynamic 
response provided by SPM. Estimated motion parameters were included in the model as 
nuisance regressors and the data was high pass filtered with a cutoff of 180 seconds. Each 
subject’s contrast estimates for stimulation “ON” condition was combined into a second 
level model in which two separate group analysis were conducted (active group only, 
control group only) using a one-sample t-test (active: ON>OFF, ON<OFF; control: 
ON>OFF, ON<OFF). The duration of the “OFF” time was unmodeled and left as the 
implicit baseline. Additionally, an overall paired t-test contrast was also conducted 
(active ON>OFF > control ON>OFF; active ON<OFF > control ON<OFF). Lastly, a 
brain stem mask was created in order to explore if regional activations in this small area 
could be detected in each of the group analyses. 
 
Results 
Participants, Stimulation, and Tolerability 
17 healthy, right-handed individuals (8 female, 9 male, mean age 25.8 SD 7.59) were 
included in this study. All participants completed both visits without any dropouts. Mean 
perceptual thresholds (PT) are as follows (mean ± SD mA): tragus 1.57 ± 0.48; earlobe 
1.22 ± 0.58. The current at which taVNS was delivered was again a scale multiplier of 
the PT (200%). Mean stimulation currents were as follow (mean ± SD mA): tragus- 3.14 
± 0.99; earlobe 2.43 ± 1.16.  Using a 2-tailed paired t-test, it was determined that there 
was no difference in perceptual threshold between the two stimulation sites (table 4-2).  
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Mean NRS scores were low, with the mean difference in pain rating between active and 
control being 0.6 on a subjective 1-10 scale in 0.5 increments (table 4-2). Although a 
paired t-test revealed this difference in pain ratings is significant, in practicality 
stimulation should be considered painless in both conditions, as maximum of  2.1 (mean 
active pain rating) on a 1-10 rating scale is insignificant pain. 
 
Whole-Brain fMRI Analysis  
Earlobe (control condition) Stimulation Only 
In the control group analysis exploring the BOLD signal changes during left earlobe 
stimulation, statistically significant increases in BOLD signal associated with stimulation 
(ON>OFF) were only found in the right inferior postcentral gyrus, operculum, and insula 
(n=17, one sample t-test, cluster FWE p<0.05, cluster forming threshold p <0.005, extent 
threshold =100 voxels) (Figure 4-4, Table 4-3). There were areas in which a significant 













PT ± SD (mA) 1.57 ± 0.48 1.22 ± 0.58 
N Stim. Current ± 
SD (mA) 3.14 ± 0.99 2.43 ± 1.16 
Mean 500us 25Hz 
NRS Pain Rating 
± SD 2.1 ± 0.87 1.43 ± 0.68 Y (p<0.01) 
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Figure 4-4 Earlobe (Control) Stimulation Only a) fMRI BOLD activations resulting 
from control stimulation only (compared to rest). (n=17, one sample t-test, cluster FWE 
p<0.05, cluster forming threshold p <0.005, extent threshold =100 voxels).  
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Tragus (active condition) Stimulation Only 
In the active group analysis exploring the BOLD signal changes during left tragus 
stimulation condition, statistically significant increases in BOLD signal associated with 
stimulation (ON>OFF) were found in similar areas as earlobe stimulation (right 
postcentral gyrus, operculum, and insula) as well as other more wide spread areas such as 
the left insula, angular gyrus, cerebellum, and bilateral frontal lobes (n=17, one sample t-
test, p<0.05 FWE corrected, cluster forming threshold p <0.005, extent threshold =100 
voxels) (figure 4-5, table 4-3). No significant deactivations were found (ON<OFF 
contrast). 
 
Tragus (active) Greater Than Earlobe (control) 
The effect of control stimulation was subtracted from the effect of active stimulation to 
analyze the group effect of taVNS compared to control. From this analysis, one can 
visualize the effects of active taVNS in two contrasts (ON>OFF, ON<OFF). When 
examining areas in which active stimulation was greater than control, significant clusters 
were found in the right mid cingulate, caudate, bilateral operculum, bilateral cerebellum, 
and bilateral anterior cingulate cortex (ACC) (paired t-test, p<0.05 FWE corrected, 
cluster forming threshold p <0.005, extent threshold =100 voxels) (Figure 4-6, Table 4-






Figure 4-5 Tragus (Active) Stimulation Only a) fMRI BOLD activations resulting from 
tragus stimulation only (compared to rest) (n=17, one sample t-test, cluster FWE p<0.05, 
cluster forming threshold p <0.005, extent threshold =100 voxels). 
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Figure 4-6 Active stimulation > control stimulation a) fMRI BOLD activations 
resulting from the contrast active > control stimulation only. (n=17, paired sample t-test, 




Table 4-3. Results from GLM analyses for active and control stimulation.  
 Cluster Statistics  Cluster Locations  Peak Location (MNI) 
 
pFWE-corr # voxels puncorrected  x y z 
Left Earlobe (Control) Stimulation 
 
0.007 165 0.001 Right Central Operculm 48 -4 8 
    
Right Postcentral Gyrus 63 -16 23 
    
Right Insula 36 -13 17 
Left Tragus (Active) Stimulation Only 
 
0 1491 0 Right Insula 36 -13 17 
    
Right Central Operculum 48 -7 8 
    
Right Postcentral Gyrus 60 -16 32 
 
0.011 359 0.001  -36 -16 11 
 
   Left Insula -39 -7 2 
 
    -39 2 -10 
 
0.007 392 0 Left Angular Gyrus -42 41 -1 
    
Left Inferior Frontal Gyrus -48 44 -16 
    
 -36 50 -16 
 
0.077 221 0.005 Left Supplementary Motor Area -9 23 47 
 
   Left Superior Frontal Gyrus -9 38 47 
    
Right Superior Frontal Gyrus -9 35 47 
 
0.082 217 0.006 Left Cerebellum -15 -70 -46 
Active Stimulation > Control Stimulation 
 
0.005 369 0  27 -7 35 
 
   Right Caudate 15 2 23 
 
   Right Mid Cingulate Gyrus 18 -4 38 
 
0 698 0 Bilateral Cerebellum 3 -58 -43 
 
    36 -58 -37 
 
    -18 -67 -40 
 
0.007 353 0 Bilateral Anterior Cingulate 3 35 11 
 
   Left Anterior Cingulate -12 26 17 
 
   Left Mid Cingulate -9 14 23 
 
0.053 221 0.003 Left Mid Frontal Gyrus -30 14 35 
 
   Left Superior Frontal Gyrus -12 26 44 
 





Brain stem analysis 
A post-hoc, brainstem analysis was conducted using an explicit mask comprised of the 
pons, midbrain, and medulla (121). Using the same thresholds on this limited region, no 
significant findings were discovered in either condition (active only, control only) or in a 
direct comparison contrast (active vs control). 
 
Discussion 
Using this taVNS/fMRI system, we have demonstrated that active taVNS in healthy 
young adults at 500µs 25Hz produces significant BOLD activations throughout cortical, 
subcortical, and cerebellar brain regions associated with the afferent vagal pathway. In 
contrast, control stimulation of the earlobe exclusively produces a contralateral 
somatosensory BOLD signal response in the postcentral gyrus representation of the face. 
When control response is subtracted from the active response in the overall contrast of 
active>control, significant activations emerge throughout the cingulate gyrus (bilateral 
ACC, bilateral mid cingulate), frontal cortex (left middle and frontal gyrus), cerebellum, 
and right caudate.  
 
We investigated the direct brain effects of taVNS to either the left tragus (active) or 
earlobe (control) using a novel taVNS/fMRI paradigm in 17 healthy individuals. Each 
participant attended two scanning sessions, in which both left tragus (active) and left 
earlobe (control) stimulation was administered in order to determine the afferent brain 
effects of electrical stimulation of the ABVN. Within this trial, we describe two effects: 
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1) the somatosensory cortical representation of the ear, and 2) the cortical and subcortical 
direct brain effects of stimulating the ABVN.  
 
Penfield described the homuncular representation of the human primary sensory cortex 
(122), and notably the ear is omitted from these trials. To date there have only been two 
studies exploring ear somatosensory representation (123, 124), the first using 
magnetoencephalography (MEG) and the second using fMRI. Both describe the 
somatosensory response of the left ear being represented on the contralateral 
somatosensory cortex in the face and neck areas. The MEG findings demonstrated that 
somatosensory evoked magnetic fields (SEFs) were produced in response to slow (1Hz), 
ultra brief (0.05ms pulse width) electrical stimulation of the earlobe. The follow-up MRI 
findings by the same group confirm initial MEG findings that slow (2Hz), brief (0.5ms 
pulse width) electrical stimulation solely activates contralateral postcentral gyrus. 
Although our stimulation current was faster (25 Hz compared to 1 and 2 Hz), the pulse 
width was identical and our control stimulation findings replicate these two sequential 
trials conducted by Nihashi et al.  
 
The afferent pathway of the ABVN is still poorly understood although it is hypothesized 
to activate the main vagal afferent pathway (via the NTS, LC, and upstream cortical 
projections as described in detail in Chapter 1) (13, 125-127). To date, excluding this 
trial, there have only been five taVNS/fMRI studies exploring the direct brain effect of 
electrical stimulation to the ear listed in table 4-1. The findings are widely variant as are 
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the methods. We have understood from prior heart rate trials described in Chapters 2 and 
3 that pulse width and frequency affect the stimulation-induced parasympathetic effect of 
taVNS. This was also described in a VNS/fMRI trial exploring pulse width effect on 
BOLD (49) Unfortunately two of the prior trials explored 250µs pulse width stimulation 
(90, 93) and two others administered 20µs stimulation (91, 92). Our trial used a 500µs 
25Hz parameter similar to Yakunina et al (89) with similar findings. Like the Yakunina 
group, we demonstrate tragus stimulation produced significant increased activation in the 
angular gyrus, caudate, cerebellum, cingulate, and frontal cortex. These regions in 
general are also found activated throughout the other smaller pulse width trials listed in 
Table 4-1 and are afferent targets of the vagus nerve pathway, suggesting ABVN 
stimulation enters the vagal bundle and projects to the brain via the brainstem.  
 
A major difference between these trials was the time of stimulation during scanning. 
Three studies stimulated for less than 1 minute (90-92), while the most recent two 
stimulated for six or seven minutes (89, 93). In our trial, stimulation was delivered for 1 
minute blocks. The studies conducting long stimulation periods reported BOLD signal 
activations in the brainstem region, while the prior three trials did not. It is difficult to 
image small brainstem regions such as the LC and NTS without rapid, thin slice 
acquisition of that region. Even in perfect conditions the breathing, moving, and 
swallowing artifacts make imaging this region of the brain a challenge. It is plausible that 
we did not see any brainstem activations due to our short stimulation period of 1 minute 
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and possible future studies should consider longer stimulation periods and scans 
optimized for imaging the brainstem rather than whole brain scans.  
 
Interestingly, the strong bilateral activation of the ACC and left DLPFC may reveal a 
potential mechanism for the anti-depressant effect of cervically implanted VNS as well as 
taVNS that has been described in the literature (33, 40, 88).  It has been demonstrated 
that the ACC is involved in cognition and emotional processing (128, 129)and has been 
shown to play a key role in the depressions, expressing reduced glutamate release (130-
132)and reduced glial cell density (133, 134) in pathologic conditions. It also has been 
used as a longitudinal predictor of treatment response in depression (135, 136). The left 
DLPFC has been demonstrated to be hypoactive in depression (137, 138) and is targeted 
with high frequency rTMS (139-142). Presented with significant BOLD activations in 
regions of the brain associated with major depression, it is reasonable to consider a 
bottom-up approach to treating MDD. Rather than pharmacological agents aimed at 
neurotransmitters, or rTMS which treats the cortex, taVNS can potentially target desired 
brain regions by entering the brain through cranial nerves and having a cortical effect 
driven from the brainstem. 
 
Limitations 
It is important to recognize some limitations in our trial. Firstly, we chose a 1 minute 
stimulation period was chosen to be consistent with our prior physiological trials. The 
safety profile of longer periods of stimulation was unknown and we did not want to risk 
107 
adverse events in the MRI scanner. Secondly, we acknowledge that there may residual 
cortical brain effects persisting in the 60s inter-stimulation rest blocks. This type of 
design was used to increase the power of our effect by increasing number of stimulation 
blocks while minimizing scanner drift of long stimulation trials. Lastly, the control region 
was chosen as the earlobe in line with prior taVNS trials, although it may not be the most 




These findings demonstrate taVNS delivered at 500µs 25Hz to the left tragus produces 
significant cortical effects in the vagal afferent pathway compared to earlobe stimulation. 
These findings are similar to prior taVNS trials. Furthermore, bilateral ACC and left 
prefrontal BOLD signal increases shed light on the ability to conduct bottom-up brain 
stimulation modalities in which stimulating cranial nerves can potentially be used as 
therapeutics. Future taVNS/fMRI trials should be conducted to explore the effect of 








CONCLUSIONS and FUTURE DIRECTIONS 
 
Summary of Findings 
This body of work aimed to address five goals. They are listed below along with their 
summarized overall findings in their respective subsections. 
1. Develop a system that stimulates the ABVN at MUSC 
2. Determine if taVNS is safe 
3. Optimize stimulation parameters using heart rate as a biomarker 
4. Develop and optimize a taVNS/fMRI method 
5. Measure the direct brain effects of taVNS using BOLD fMRI 
 
Develop a system that stimulates the ABVN at MUSC 
This body of work began in 2014, and at that time there was one commercially available 
ABVN stimulation unit on the market sold under the name NEMOS© (Cerbomed 
GMBH, Germany). It is not sold in the United States, and there were several issues 
associated with using a commercially available device. Firstly, stimulation parameters 
(pulse width, frequency, duration) are not modifiable making it difficult to use them in 
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laboratory-controlled trials. Secondly, the stimulation electrodes target the cymba 
conchae of the ear, which is a different primary site of active stimulation than had been 
chosen for these trials (tragus stimulation/ear canal). As of 2017 this commercially 
available company has unfortunately declared bankruptcy and no longer sells these 
devices. For these reasons, it became important to develop a standalone, independent 
system at MUSC that has completely modifiable parameters and ability to stimulate 
various ear targets. 
 
A stimulation electrode was built by Bashar and Alan Badran, made of 1cm diameter 
round cup electrodes (cupped in order to hold conductive gel) that were affixed to each 
other in a custom clip arrangement, forming what are essentially direct electrical current 
clamps that can stimulate either the tragus (active) or earlobe (control). These are 
pictured in the Methods section of Chapter 2. 
 
In order to avoid filing an Investigational Device Exemption (IDE) with the FDA as 
required by the MUSC IRB, the constant current stimulator used was required to be 
FDA-cleared. The custom electrodes were modified to be compatible with the Digitimer 
DS7a stimulator, which was used for all three stimulation trials. This stimulator allowed 
for easy and reliable parametric modifications, most importantly changing pulse width, 
frequency, current, and stimulation duration. The custom electrodes paired with the 
stimulator allowed for a variety of experimental taVNS studies to be easily conducted. 
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Determine if taVNS is safe 
Given the parasympathetic efferent projections of the vagus nerve described in Chapter 1, 
the primary safety concern was the potential of adverse cardiac events. Cervically 
implanted VNS has a long history of animal and human safety and feasibility trials(36, 
42, 99, 100). taVNS is a relative newcomer, having been formally proposed in 2000 and 
lacking the large number of prospective human trials. There had been several prior 
reports that were published while the safety trials were conducted suggesting its safe use 
(84, 88, 143-145), although parameters were highly inconsistent and variable.  
 
The first subjects of our initial HR trial were conducted in the electroconvulsive therapy 
suite at MUSC. Dr. Mark George was the first subject to receive stimulation from our 
custom taVNS system. Before the experimental visit started, Dr. George asked Bashar 
“Do you know how to call 9-1-1?” Retrospectively, that comment sounds rather 
egregious, but it accurately conveys the perceived safety risk and concern of the research 
team working with this new modality.  
 
Our systematic testing of the effects of nine different taVNS parameters on immediate 
decrease in heart rate established that 1-minute stimulation sessions of tragus stimulation 
elicits a safe, relatively minor decrease in heart rate during stimulation. No adverse 
events were reported in any of the three trials conducted. Redness was perceived at the 
stimulation site that resolved after several minutes. taVNS was determined to be safe in 
our stimulation paradigms. 
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Optimize stimulation parameters using heart rate as a biomarker 
We conducted two physiological trials exploring the effects of taVNS on HR described in 
Chapters 2 and 3 of this dissertation. The first trial in 15 healthy individuals revealed no 
overall effect of active taVNS (vs control) in heart rate during the stimulation period. 
Upon multivariate analysis of each of the nine individual parameters, significant effects 
on HR were discovered in several parameters, suggesting the parasympathetic activation 
via taVNS is parameter specific. The optimal parameters at modulating HR in this trial 
were 500µs 10Hz and 25Hz.  
 
Following this initial study, we conducted a follow-up confirmatory study was conducted 
in 20 healthy individuals exploring the effects on HR of the two optimal parameters 
(500µs 10Hz, 500µs 25Hz) against each other and against control stimulation. In this 
trial, when both parameters were combined, active taVNS produced significant decreases 
in HR during stimulation period compared to control stimulation. Upon individual 
parameter analysis, both parameters produced decreases in HR during the stimulation 
period, although the optimal parameter determined to activate parasympathetic decrease 
in HR compared to control was 500µs 10Hz. These sequential trials suggest parametric-
specific effects of taVNS on the parasympathetic nervous system possibly modulated by 
the ABVN and vagal pathway. 
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Develop and optimize taVNS/fMRI method 
We developed a non-ferromagnetic MRI-compatible system that can safely and reliably 
stimulate the ABVN through the tragus and earlobe in order to conduct taVNS in the 
magnetic field of the fMRI scanner. As described in Chapter 4 were the three roadblocks 
(heating of electrodes, induced currents, MRI artifact) were surmounted using a variety of 
electronic and manufacturing achievements. Electrodes were fabricated out of 3D printed 
plastic and Ag/AgCl materials; 5kΩ resistors were placed in the copper stimulation wires 
(insulated with PVC); and a grounded RF filter attached to a patch panel in the wall 
adjacent to the scanner room was used to solve all these potential pain points. 
 
After fabrication of all components, three separate quality control scans were conducted 
on MRI phantoms in order to confirm electrical stimulation in the MRI scanner did not 
disrupt the image acquisition and that heating was minimal. Subsequently two pilot scans 
were completed on healthy individuals to confirm scanning was feasible and safe. This 
development process created one of less than five MRI-compatible taVNS systems in the 
United States as of 2017.  
 
Measure the direct brain effects of taVNS using BOLD fMRI 
We conducted a two-visit trial in 17 healthy individuals in which participants received 
either active (tragus) or control (earlobe) taVNS stimulation (via our custom 
taVNS/fMRI system), while imaging the direct brain effects using fMRI. The control 
stimulation only group analysis revealed significant BOLD activation in exclusively the 
113 
primary somatosensory cortex while the active stimulation only group produced 
significant global cortical and subcortical BOLD activations. Of note, active taVNS 
activated the bilateral insula, bilateral frontal cortex, and similar somatosensory 
activation as control. 
 
The main contrast explored the overall BOLD effects of taVNS significantly greater than 
control (active>control, paired t-test), which revealed significant activations in the 
bilateral anterior cingulate, bilateral cerebellum, left frontal cortex, and right caudate. 
These findings suggest taVNS stimulates the afferent vagal pathway, supporting the 
hypothesis that the ABVN that innervates the ear most likely joins the main vagal bundle 
and enters the brain to affect similar neuroanatomical structures. These data are in line 
with the few taVNS/fMRI studies in the literature. Of notable difference, this study did 
not discover any brainstem or midbrain activations, as suggested by two of the prior 




Heart Rate Trials 
There are three limitations to consider and improve upon from these heart rate trials. 
Firstly, one cannot be certain that stimulating the tragus or any part of the ear is directly 
stimulating the ABVN. There is one prior study in which dissections of the ear reveal the 
underlying nerves (81). It is revealed that only 45% of the dissections in their sample 
114 
contained ABVN innervation in the tragus and ear canal. This plausibly can introduce the 
high level of variance between individual effects of taVNS, especially at low stimulation 
parameters. It is nearly impossible to determine the nerve innervation in individual 
participants before conducting a trial, so this limitation may persist until noninvasive 
subcutaneous nerve mapping technology becomes available. 
 
Secondly, there is a decrease in heart rate that is sustained in the control group. It is still 
unknown what causes this bradycardia. One hypothesis is that this earlobe-induced 
bradycardia could be due to “electrical bleed” from the earlobe to closely innervating 
ABVN projections. The distance between the earlobe and tragus is less than 3cm on 
average, and of all possible controls, earlobe stimulation is arguably the most stringent. 
Studies like this require these active control sites to definitively conclude the findings.  
 
Lastly, perhaps heart rate is not the most effective surrogate marker of vagal activity in 
taVNS trials, especially given the bidirectional communication of the vagal nerve. It is 
difficult to determine whether the effects on HR are due to direct efferent projections to 
the heart (ear->heart) or whether these effects are relayed up (afferent pathway) to the 
brainstem and loop back down to target efferent targets.   
 
fMRI Trial 
A major limitation in the fMRI trial is that the stimulation time (60s) may not have been 
long enough to capture the BOLD signal response to stimulation in the brainstem. This 
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trial was only the sixth taVNS/fMRI exploring the afferent effects of ABVN stimulation 
(See Chapter 4, Table 1), and only two of the prior studies (89, 93) demonstrated 
brainstem effects that suggest ABVN stimulation enters the brain via the NTS in an 
identical manner as the cervical vagus nerve. One trial stimulated an “ON” period of 6 
minutes, and another trial stimulated an “ON” period for 7 minutes. The remaining trials 
with short stimulation periods reveal no brain stem activity. It is difficult to say that it is 




Further Optimization of Parameters 
These trials, although highly promising, are not conclusive as to whether a higher pulse 
width of 500µs or higher frequencies of 10-25Hz are the optimal stimulation parameters 
for taVNS. Although these results demonstrate biologic effects on heart rate and central 
effects of the vagus afferent projections measured by fMRI, further parametric 
optimization needs to be conducted.  
 
These physiological trials were conducted in a laboratory setting with individuals laying 
supine and a resting HR. This was considered a conservative position and paradigm for 
exploring effects of a parasympathetic modulator. Future parametric explorations should 
be conducted in high stress situations in which the sympathetic nervous system is active 
and attempt to modulate it by activating the reciprocal parasympathetic nervous system. 
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This may yield larger effect sizes and possibly decrease the amount of response earlobe 
stimulation produces. Potential autonomic blockade with pharmacological agents could 
also be used to knock out the active taVNS potential effect. 
 
Conducting parametric explorations of taVNS will be integral in moving this technology 
forward. Similar to a pulse-width study conducted at MUSC with cervical VNS/fMRI 
(146, 147), various pulse widths and frequencies can be conducted in the MRI scanner 
and capture the neurophysiological signature of the stimulation. These fMRI studies are 
time and cost intensive, so it would be prudent to conduct trials exploring taVNS on 
surrogate markers of vagus activation or EEG before going into the fMRI scanner, similar 
to how these sequential HR and fMRI trials were conducted. 
 
Aside from pulse width and frequency, duty cycle must be explored. Given the BOLD 
signal changes observed in longer stimulation periods (>6 minutes), perhaps taVNS is not 
as powerful as cervically implanted VNS. All taVNS trials are following the parameter 
space of cervically implanted VNS described in the early 1990’s (23, 24, 148), although 
the mechanism and fibers could be completely different when delivered through the ear. 
There are only disperse nerve projections in the ear rather than the large bundle of the 
vagus nerve and it is plausible that rather than mimicking the short “ON” period of 
therapeutic VNS, longer “ON” periods must be explored in future therapeutic trials to 
potentially deliver identical signals to the brainstem.  
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Perhaps rather than pulse width, frequency, or stimulation time being the issues, the 
strength of electrical stimulation may have been under-dosed, possibly limiting the 
robustness of the effects Our studies reveal at 200% PT, taVNS is painless, rating on 
average a 2.1 on a 1-10 scale. Aside from safety concerns which were appeased during 
preliminary trials, future studies should potentially explore increasing dosage to 3-400% 
PT in order to determine whether stimulation intensity matters, or maintaining a lower PT 
and administering bilateral taVNS to double the signal entering the brain. The field of 
taVNS is still very new and these parameters must be worked out in order to have an 
effective noninvasive modality.  
 
taVNS Induced Plasticity & Therapeutic Potential 
A budding area of VNS research is the area known as targeted plasticity (66), 
championed by a team of researchers at the University of Texas, Dallas. This team has 
demonstrated that stimulating the cervical vagus nerve in conjunction with various 
therapies produces significant cortical reorganization properties as measured by single 
channel electrode recordings in rodents (70). Most notably, this pairing of VNS with 
specific audio tones has been shown to treat and reverse tinnitus (65, 68) and paired with 
rehabilitation paradigms to restore motor behavior in stroke (69, 149). These paradigms 
have been successfully translated from animal models to human clinical trials (71-73) and 
It is conceivable that these targeted plasticity findings can feasibly and easily be 
translatable with taVNS without the cost or risk of surgical implantation. 
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Pairing taVNS with specific therapy has yet to emerge as an area of study. There are two 
open label, small sample trials which attempted taVNS paired with tones to treat tinnitus 
(87, 150) with minimal effects. These findings could be more promising if the proper 
stimulation parameter optimization is conducted beforehand. Aside from paring taVNS 
with tones, there have been no other paired taVNS trials and this area needs to be 
explored as a potential treatment modality.  
 
taVNS can be used in a similar manner as conventional VNS where pulses are delivered 
constantly for a long period of time (months to years). It is still unknown what the 
optimal dosing paradigm would be, as cervical VNS cycles between on and off periods 
constantly for many years until the battery needs to be replaced. Suggested daily use 
sessions on the scale of hours would likely be a starting point of therapeutic delivery. 
Many of the animal and human studies exploring the use of implantable VNS for central 
and peripheral disorders described in Chapter 1, such as epilepsy, depression, obesity, 
stroke, and heart disease could be explored with taVNS and easily translated to humans 
(98, 151-155). There have been some early trials exploring the use of various parameters 
of taVNS for the treatment of depression (88, 156, 157), autism (158) tinnitus (85) and 
pain (159-161) all revealing small effect sizes and mixed results.  
 
The main problem encountered with taVNS as a take home therapy is the lack of 
practicality as a long term therapeutic modality. The majority of patients that will respond 
to cervically implanted VNS therapy for epilepsy or depression do so 12 months post-
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implantation (162). This delayed response would require daily use of a taVNS device for 
multiple sessions per day, over a period of at least one year while maintaining patient 
compliance. More realistically, taVNS will most likely be used as an intermediary device 
that will predict response, guiding which individuals would make good candidates for 
surgical implantation rather than used as a long term therapeutic modality. 
 
This body of work aims to take the first step in optimizing taVNS. For taVNS to become 
a possible future noninvasive therapeutic device in the future, further development is 
needed before rushing to clinical trials. Using physiological measures along with 
functional neuroimaging trials such as fMRI BOLD to determine optimal stimulation 
parameters will lead to more effective, noninvasive treatments for a variety of 
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